{
  "tier": 3,
  "name": "Complex Designs",
  "description": "Complex trial designs including bioequivalence, group sequential, adaptive, multilevel, non-inferiority, and factorial",
  "tasks": [
    {
      "id": "t3-mk-powermpeknownvar-041",
      "template": "multiple_endpoints",
      "difficulty": "advanced",
      "question": "A dermatologist has 198 participants for a group sequential design with interim analyses studying hypertension. What power is achieved at significance level of 0.05?",
      "expected_template": "multiple_endpoints",
      "ground_truth": {
        "sample_size": 198,
        "power": 0.8
      },
      "tolerance": {
        "sample_size": 4,
        "power": 0.016
      },
      "source": {
        "package": "MKpower",
        "function": "power.mpe.known.var",
        "origin": "MKpower::power.mpe.known.var CRAN documentation",
        "variation": "mpe_known_K3_rho03"
      },
      "reference_code": "library(MKpower)\npower.mpe.known.var(K=3, delta=c(0.25, 0.5, 0.75), SD=c(1,1,1), rho=c(0.3, 0.3, 0.3), power=0.80, sig.level=0.05)",
      "tier": 3
    },
    {
      "id": "t3-mk-powermpeknownvar-042",
      "template": "multiple_endpoints",
      "difficulty": "intermediate",
      "question": "A ophthalmologist has 64 participants for a group sequential design with interim analyses studying type 2 diabetes. What power is achieved at significance level of 0.05?",
      "expected_template": "multiple_endpoints",
      "ground_truth": {
        "sample_size": 64,
        "power": 0.8
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.016
      },
      "source": {
        "package": "MKpower",
        "function": "power.mpe.known.var",
        "origin": "MKpower::power.mpe.known.var CRAN documentation",
        "variation": "mpe_known_K2_rho05"
      },
      "reference_code": "library(MKpower)\npower.mpe.known.var(K=2, delta=c(0.5, 0.5), SD=c(1,1), rho=0.5, power=0.80, sig.level=0.05)",
      "tier": 3
    },
    {
      "id": "t3-mk-powermpeatleastone-043",
      "template": "multiple_endpoints",
      "difficulty": "advanced",
      "question": "A nephrologist has 44 participants for a group sequential design with interim analyses studying major depressive disorder. What power is achieved at significance level of 0.05?",
      "expected_template": "multiple_endpoints",
      "ground_truth": {
        "sample_size": 44,
        "power": 0.8
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016
      },
      "source": {
        "package": "MKpower",
        "function": "power.mpe.atleast.one",
        "origin": "MKpower::power.mpe.atleast.one CRAN documentation",
        "variation": "mpe_atleast1_K2_rho05"
      },
      "reference_code": "library(MKpower)\npower.mpe.atleast.one(K=2, delta=c(0.5, 0.5), SD=c(1,1), rho=0.5, power=0.80)",
      "tier": 3
    },
    {
      "id": "t3-mk-powermpeatleastone-044",
      "template": "multiple_endpoints",
      "difficulty": "advanced",
      "question": "A infectious disease specialist has 101 participants for a group sequential design with interim analyses studying chronic pain. What power is achieved at significance level of 0.05?",
      "expected_template": "multiple_endpoints",
      "ground_truth": {
        "sample_size": 101,
        "power": 0.8
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.016
      },
      "source": {
        "package": "MKpower",
        "function": "power.mpe.atleast.one",
        "origin": "MKpower::power.mpe.atleast.one CRAN documentation",
        "variation": "mpe_atleast1_K3_rho03"
      },
      "reference_code": "library(MKpower)\npower.mpe.atleast.one(K=3, delta=c(0.3, 0.3, 0.3), SD=c(1,1,1), rho=c(0.3, 0.3, 0.3), power=0.80)",
      "tier": 3
    },
    {
      "id": "t3-pupr-001",
      "template": "individual_rct",
      "difficulty": "basic",
      "question": "An hematologist is designing a individual-level randomized trial . The expected effect size is 0.25. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "n": 504
      },
      "tolerance": {
        "n": 26
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.ira",
        "origin": "PowerUpR::mrss.ira CRAN documentation",
        "variation": "ira_es25_p80"
      },
      "reference_code": "library(PowerUpR)\nmrss.ira(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE)",
      "tier": 3
    },
    {
      "id": "t3-pupr-002",
      "template": "individual_rct",
      "difficulty": "basic",
      "question": "An clinical nutritionist is designing a individual-level randomized trial . The expected effect size is 0.2. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "n": 787
      },
      "tolerance": {
        "n": 40
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.ira",
        "origin": "PowerUpR::mrss.ira CRAN documentation",
        "variation": "ira_es20_p80"
      },
      "reference_code": "library(PowerUpR)\nmrss.ira(es=0.20, power=0.80, alpha=0.05, two.tailed=TRUE)",
      "tier": 3
    },
    {
      "id": "t3-pupr-003",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An rehabilitation specialist is designing a individual-level randomized trial . The expected effect size is 0.25. At significance level of 0.05 with 90% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "n": 674
      },
      "tolerance": {
        "n": 34
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.ira",
        "origin": "PowerUpR::mrss.ira CRAN documentation",
        "variation": "ira_es25_p90"
      },
      "reference_code": "library(PowerUpR)\nmrss.ira(es=0.25, power=0.90, alpha=0.05, two.tailed=TRUE)",
      "tier": 3
    },
    {
      "id": "t3-pupr-004",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An occupational therapist is designing a individual-level randomized trial . The expected effect size is 0.25. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "n": 253
      },
      "tolerance": {
        "n": 13
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.ira",
        "origin": "PowerUpR::mrss.ira CRAN documentation",
        "variation": "ira_es25_r21_50"
      },
      "reference_code": "library(PowerUpR)\nmrss.ira(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, r21=0.50)",
      "tier": 3
    },
    {
      "id": "t3-pupr-005",
      "template": "individual_rct",
      "difficulty": "basic",
      "question": "An speech pathologist is running a individual-level randomized trial . The expected effect size is 0.25. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "power": 0.4205
      },
      "tolerance": {
        "power": 0.0126
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.ira",
        "origin": "PowerUpR::power.ira CRAN documentation",
        "variation": "power_ira_n200"
      },
      "reference_code": "library(PowerUpR)\npower.ira(es=0.25, alpha=0.05, two.tailed=TRUE, n=200)",
      "tier": 3
    },
    {
      "id": "t3-pupr-006",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An physical therapist is running a individual-level randomized trial . The expected effect size is 0.2. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "power": 0.6071
      },
      "tolerance": {
        "power": 0.0182
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.ira",
        "origin": "PowerUpR::power.ira CRAN documentation",
        "variation": "power_ira_n500_es20"
      },
      "reference_code": "library(PowerUpR)\npower.ira(es=0.20, alpha=0.05, two.tailed=TRUE, n=500)",
      "tier": 3
    },
    {
      "id": "t3-pupr-007",
      "template": "individual_rct",
      "difficulty": "basic",
      "question": "An cardiologist has a individual-level randomized trial . With 80% power and significance level of 0.05 using a two-sided test, what is the minimum detectable effect size?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "mdes": 0.3982
      },
      "tolerance": {
        "mdes": 0.0119
      },
      "source": {
        "package": "PowerUpR",
        "function": "mdes.ira",
        "origin": "PowerUpR::mdes.ira CRAN documentation",
        "variation": "mdes_ira_n200"
      },
      "reference_code": "library(PowerUpR)\nmdes.ira(power=0.80, alpha=0.05, two.tailed=TRUE, n=200)",
      "tier": 3
    },
    {
      "id": "t3-pupr-008",
      "template": "cluster_rct_2level",
      "difficulty": "basic",
      "question": "An oncologist is designing a 2-level cluster randomized trial with 20 individuals per cluster. The expected effect size is 0.25. The ICC at level 2 is 0.1. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "J": 75
      },
      "tolerance": {
        "J": 4
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra2",
        "origin": "PowerUpR::mrss.cra2 CRAN documentation",
        "variation": "cra2_es25_n20_rho10"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra2(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=20, rho2=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-009",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An neurologist is designing a 2-level cluster randomized trial with 30 individuals per cluster. The expected effect size is 0.2. The ICC at level 2 is 0.05. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "J": 66
      },
      "tolerance": {
        "J": 4
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra2",
        "origin": "PowerUpR::mrss.cra2 CRAN documentation",
        "variation": "cra2_es20_n30_rho05"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra2(es=0.20, power=0.80, alpha=0.05, two.tailed=TRUE, n=30, rho2=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-010",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An psychiatrist is designing a 2-level cluster randomized trial with 20 individuals per cluster. The expected effect size is 0.25. The ICC at level 2 is 0.1. At significance level of 0.05 with 90% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "J": 100
      },
      "tolerance": {
        "J": 5
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra2",
        "origin": "PowerUpR::mrss.cra2 CRAN documentation",
        "variation": "cra2_es25_n20_p90"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra2(es=0.25, power=0.90, alpha=0.05, two.tailed=TRUE, n=20, rho2=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-011",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An pediatrician is designing a 2-level cluster randomized trial with 20 individuals per cluster. The expected effect size is 0.25. The ICC at level 2 is 0.2. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "J": 123
      },
      "tolerance": {
        "J": 7
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra2",
        "origin": "PowerUpR::mrss.cra2 CRAN documentation",
        "variation": "cra2_es25_n20_rho20"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra2(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=20, rho2=0.20)",
      "tier": 3
    },
    {
      "id": "t3-pupr-012",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An endocrinologist is designing a 2-level cluster randomized trial with 20 individuals per cluster. The expected effect size is 0.25. The ICC at level 2 is 0.1. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "J": 50
      },
      "tolerance": {
        "J": 3
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra2",
        "origin": "PowerUpR::mrss.cra2 CRAN documentation",
        "variation": "cra2_es25_r22_50"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra2(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=20, rho2=0.10, r22=0.50)",
      "tier": 3
    },
    {
      "id": "t3-pupr-013",
      "template": "cluster_rct_2level",
      "difficulty": "basic",
      "question": "An orthopedic surgeon is running a 2-level cluster randomized trial with 20 individuals per cluster. The expected effect size is 0.25. The ICC at level 2 is 0.1. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "power": 0.2848
      },
      "tolerance": {
        "power": 0.01
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.cra2",
        "origin": "PowerUpR::power.cra2 CRAN documentation",
        "variation": "power_cra2_J20_n20"
      },
      "reference_code": "library(PowerUpR)\npower.cra2(es=0.25, alpha=0.05, two.tailed=TRUE, n=20, J=20, rho2=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-014",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An gastroenterologist is running a 2-level cluster randomized trial with 30 individuals per cluster. The expected effect size is 0.25. The ICC at level 2 is 0.1. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "power": 0.5703
      },
      "tolerance": {
        "power": 0.0171
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.cra2",
        "origin": "PowerUpR::power.cra2 CRAN documentation",
        "variation": "power_cra2_J40_n30"
      },
      "reference_code": "library(PowerUpR)\npower.cra2(es=0.25, alpha=0.05, two.tailed=TRUE, n=30, J=40, rho2=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-015",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An pulmonologist has a 2-level cluster randomized trial with 20 individuals per cluster. The ICC at level 2 is 0.1. With 80% power and significance level of 0.05 using a two-sided test, what is the minimum detectable effect size?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "mdes": 0.5046
      },
      "tolerance": {
        "mdes": 0.0151
      },
      "source": {
        "package": "PowerUpR",
        "function": "mdes.cra2",
        "origin": "PowerUpR::mdes.cra2 CRAN documentation",
        "variation": "mdes_cra2_J20_n20"
      },
      "reference_code": "library(PowerUpR)\nmdes.cra2(power=0.80, alpha=0.05, two.tailed=TRUE, n=20, J=20, rho2=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-016",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An rheumatologist has a 2-level cluster randomized trial with 30 individuals per cluster. The ICC at level 2 is 0.05. With 80% power and significance level of 0.05 using a two-sided test, what is the minimum detectable effect size?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "mdes": 0.2312
      },
      "tolerance": {
        "mdes": 0.01
      },
      "source": {
        "package": "PowerUpR",
        "function": "mdes.cra2",
        "origin": "PowerUpR::mdes.cra2 CRAN documentation",
        "variation": "mdes_cra2_J50_n30"
      },
      "reference_code": "library(PowerUpR)\nmdes.cra2(power=0.80, alpha=0.05, two.tailed=TRUE, n=30, J=50, rho2=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-017",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An dermatologist is designing a individual-level randomized trial . The expected effect size is 0.25. The ICC at level 2 is 0.1. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "J": 31
      },
      "tolerance": {
        "J": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.bira2",
        "origin": "PowerUpR::mrss.bira2 CRAN documentation",
        "variation": "bira2_es25_n20_omega05"
      },
      "reference_code": "library(PowerUpR)\nmrss.bira2(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=20, rho2=0.10, omega2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-018",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An ophthalmologist is designing a individual-level randomized trial . The expected effect size is 0.2. The ICC at level 2 is 0.05. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "J": 32
      },
      "tolerance": {
        "J": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.bira2",
        "origin": "PowerUpR::mrss.bira2 CRAN documentation",
        "variation": "bira2_es20_n30_omega05"
      },
      "reference_code": "library(PowerUpR)\nmrss.bira2(es=0.20, power=0.80, alpha=0.05, two.tailed=TRUE, n=30, rho2=0.05, omega2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-019",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An nephrologist is designing a individual-level randomized trial . The expected effect size is 0.3. The ICC at level 2 is 0.1. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "J": 21
      },
      "tolerance": {
        "J": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.bira2",
        "origin": "PowerUpR::mrss.bira2 CRAN documentation",
        "variation": "bira2_es30_cov30"
      },
      "reference_code": "library(PowerUpR)\nmrss.bira2(es=0.30, power=0.80, alpha=0.05, two.tailed=TRUE, n=15, rho2=0.10, omega2=0.5, r21=0.30)",
      "tier": 3
    },
    {
      "id": "t3-pupr-020",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An infectious disease specialist is running a individual-level randomized trial . The expected effect size is 0.25. The ICC at level 2 is 0.1. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "power": 0.5997
      },
      "tolerance": {
        "power": 0.018
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.bira2",
        "origin": "PowerUpR::power.bira2 CRAN documentation",
        "variation": "power_bira2_J20"
      },
      "reference_code": "library(PowerUpR)\npower.bira2(es=0.25, alpha=0.05, two.tailed=TRUE, n=20, J=20, rho2=0.10, omega2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-021",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An psychologist has a individual-level randomized trial . The ICC at level 2 is 0.1. With 80% power and significance level of 0.05 using a two-sided test, what is the minimum detectable effect size?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "mdes": 0.3168
      },
      "tolerance": {
        "mdes": 0.01
      },
      "source": {
        "package": "PowerUpR",
        "function": "mdes.bira2",
        "origin": "PowerUpR::mdes.bira2 CRAN documentation",
        "variation": "mdes_bira2_J20"
      },
      "reference_code": "library(PowerUpR)\nmdes.bira2(power=0.80, alpha=0.05, two.tailed=TRUE, n=20, J=20, rho2=0.10, omega2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-022",
      "template": "cluster_rct_3level",
      "difficulty": "intermediate",
      "question": "An educational researcher is designing a 3-level cluster randomized trial with 20 individuals per level-2 unit and 10 level-2 units per level-3 unit. The expected effect size is 0.25. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_3level",
      "ground_truth": {
        "K": 34
      },
      "tolerance": {
        "K": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra3",
        "origin": "PowerUpR::mrss.cra3 CRAN documentation",
        "variation": "cra3_es25_n20_J10"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra3(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=20, J=10, rho2=0.10, rho3=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-023",
      "template": "cluster_rct_3level",
      "difficulty": "advanced",
      "question": "An epidemiologist is designing a 3-level cluster randomized trial with 15 individuals per level-2 unit and 8 level-2 units per level-3 unit. The expected effect size is 0.2. The ICC at level 2 is 0.1. The ICC at level 3 is 0.1. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_3level",
      "ground_truth": {
        "K": 96
      },
      "tolerance": {
        "K": 5
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra3",
        "origin": "PowerUpR::mrss.cra3 CRAN documentation",
        "variation": "cra3_es20_rho3_10"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra3(es=0.20, power=0.80, alpha=0.05, two.tailed=TRUE, n=15, J=8, rho2=0.10, rho3=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-024",
      "template": "cluster_rct_3level",
      "difficulty": "intermediate",
      "question": "An nurse researcher is running a 3-level cluster randomized trial with 20 individuals per level-2 unit and 10 level-2 units per level-3 unit. The expected effect size is 0.25. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "cluster_rct_3level",
      "ground_truth": {
        "power": 0.2799
      },
      "tolerance": {
        "power": 0.01
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.cra3",
        "origin": "PowerUpR::power.cra3 CRAN documentation",
        "variation": "power_cra3_K10"
      },
      "reference_code": "library(PowerUpR)\npower.cra3(es=0.25, alpha=0.05, two.tailed=TRUE, n=20, J=10, K=10, rho2=0.10, rho3=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-025",
      "template": "cluster_rct_3level",
      "difficulty": "advanced",
      "question": "An social scientist is running a 3-level cluster randomized trial with 20 individuals per level-2 unit and 10 level-2 units per level-3 unit. The expected effect size is 0.25. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "cluster_rct_3level",
      "ground_truth": {
        "power": 0.7413
      },
      "tolerance": {
        "power": 0.0222
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.cra3",
        "origin": "PowerUpR::power.cra3 CRAN documentation",
        "variation": "power_cra3_K30"
      },
      "reference_code": "library(PowerUpR)\npower.cra3(es=0.25, alpha=0.05, two.tailed=TRUE, n=20, J=10, K=30, rho2=0.10, rho3=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-026",
      "template": "cluster_rct_3level",
      "difficulty": "advanced",
      "question": "An pharmacist researcher has a 3-level cluster randomized trial with 20 individuals per level-2 unit and 10 level-2 units per level-3 unit. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. With 80% power and significance level of 0.05 using a two-sided test, what is the minimum detectable effect size?",
      "expected_template": "cluster_rct_3level",
      "ground_truth": {
        "mdes": 0.3359
      },
      "tolerance": {
        "mdes": 0.0101
      },
      "source": {
        "package": "PowerUpR",
        "function": "mdes.cra3",
        "origin": "PowerUpR::mdes.cra3 CRAN documentation",
        "variation": "mdes_cra3_K20"
      },
      "reference_code": "library(PowerUpR)\nmdes.cra3(power=0.80, alpha=0.05, two.tailed=TRUE, n=20, J=10, K=20, rho2=0.10, rho3=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-027",
      "template": "cluster_rct_4level",
      "difficulty": "advanced",
      "question": "An gerontologist is designing a 4-level cluster randomized trial . The expected effect size is 0.25. The ICC at level 2 is 0.05. The ICC at level 3 is 0.05. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_4level",
      "ground_truth": {
        "L": 35
      },
      "tolerance": {
        "L": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra4",
        "origin": "PowerUpR::mrss.cra4 CRAN documentation",
        "variation": "cra4_es25"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra4(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=10, J=5, K=5, rho2=0.05, rho3=0.05, rho4=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-028",
      "template": "cluster_rct_4level",
      "difficulty": "advanced",
      "question": "An sports medicine physician is running a 4-level cluster randomized trial . The expected effect size is 0.25. The ICC at level 2 is 0.05. The ICC at level 3 is 0.05. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "cluster_rct_4level",
      "ground_truth": {
        "power": 0.5433
      },
      "tolerance": {
        "power": 0.0163
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.cra4",
        "origin": "PowerUpR::power.cra4 CRAN documentation",
        "variation": "power_cra4_L20"
      },
      "reference_code": "library(PowerUpR)\npower.cra4(es=0.25, alpha=0.05, two.tailed=TRUE, n=10, J=5, K=5, L=20, rho2=0.05, rho3=0.05, rho4=0.05)",
      "tier": 3
    },
    {
      "id": "t3-pupr-029",
      "template": "individual_rct",
      "difficulty": "advanced",
      "question": "An allergist is designing a individual-level randomized trial . The expected effect size is 0.25. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "K": 8
      },
      "tolerance": {
        "K": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.bira3",
        "origin": "PowerUpR::mrss.bira3 CRAN documentation",
        "variation": "bira3_es25_omega05"
      },
      "reference_code": "library(PowerUpR)\nmrss.bira3(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=20, J=10, rho2=0.10, rho3=0.05, omega2=0.5, omega3=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-030",
      "template": "individual_rct",
      "difficulty": "advanced",
      "question": "An urologist is running a individual-level randomized trial . The expected effect size is 0.25. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "power": 0.8993
      },
      "tolerance": {
        "power": 0.027
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.bira3",
        "origin": "PowerUpR::power.bira3 CRAN documentation",
        "variation": "power_bira3_K10"
      },
      "reference_code": "library(PowerUpR)\npower.bira3(es=0.25, alpha=0.05, two.tailed=TRUE, n=20, J=10, K=10, rho2=0.10, rho3=0.05, omega2=0.5, omega3=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-031",
      "template": "cluster_rct_3level",
      "difficulty": "advanced",
      "question": "An hematologist is designing a 3-level cluster randomized trial with 20 individuals per level-2 unit and 10 level-2 units per level-3 unit. The expected effect size is 0.25. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "cluster_rct_3level",
      "ground_truth": {
        "K": 12
      },
      "tolerance": {
        "K": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.bcra3r2",
        "origin": "PowerUpR::mrss.bcra3r2 CRAN documentation",
        "variation": "bcra3r2_es25"
      },
      "reference_code": "library(PowerUpR)\nmrss.bcra3r2(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=20, J=10, rho2=0.10, rho3=0.05, omega3=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-032",
      "template": "cluster_rct_3level",
      "difficulty": "advanced",
      "question": "An clinical nutritionist is running a 3-level cluster randomized trial with 20 individuals per level-2 unit and 10 level-2 units per level-3 unit. The expected effect size is 0.25. The ICC at level 2 is 0.1. The ICC at level 3 is 0.05. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "cluster_rct_3level",
      "ground_truth": {
        "power": 0.8814
      },
      "tolerance": {
        "power": 0.0264
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.bcra3r2",
        "origin": "PowerUpR::power.bcra3r2 CRAN documentation",
        "variation": "power_bcra3r2_K15"
      },
      "reference_code": "library(PowerUpR)\npower.bcra3r2(es=0.25, alpha=0.05, two.tailed=TRUE, n=20, J=10, K=15, rho2=0.10, rho3=0.05, omega3=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-033",
      "template": "partially_nested_rct",
      "difficulty": "advanced",
      "question": "An rehabilitation specialist is designing a 2-level partially nested cluster randomized trial . The expected effect size is 0.25. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "partially_nested_rct",
      "ground_truth": {
        "J": 82
      },
      "tolerance": {
        "J": 5
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.cra2_pn",
        "origin": "PowerUpR::mrss.cra2_pn CRAN documentation",
        "variation": "pn_cra2_es25"
      },
      "reference_code": "library(PowerUpR)\nmrss.cra2_pn(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=15, rho2_trt=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-034",
      "template": "partially_nested_rct",
      "difficulty": "advanced",
      "question": "An occupational therapist is running a 2-level partially nested cluster randomized trial . The expected effect size is 0.25. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "partially_nested_rct",
      "ground_truth": {
        "power": 0.5814
      },
      "tolerance": {
        "power": 0.0174
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.cra2_pn",
        "origin": "PowerUpR::power.cra2_pn CRAN documentation",
        "variation": "power_pn_cra2_J50"
      },
      "reference_code": "library(PowerUpR)\npower.cra2_pn(es=0.25, alpha=0.05, two.tailed=TRUE, n=15, J=50, rho2_trt=0.10)",
      "tier": 3
    },
    {
      "id": "t3-pupr-035",
      "template": "individual_rct",
      "difficulty": "advanced",
      "question": "An speech pathologist is designing a individual-level randomized trial . The expected effect size is 0.25. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "J": 38
      },
      "tolerance": {
        "J": 2
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.bira2_pn",
        "origin": "PowerUpR::mrss.bira2_pn CRAN documentation",
        "variation": "pn_bira2_es25"
      },
      "reference_code": "library(PowerUpR)\nmrss.bira2_pn(es=0.25, power=0.80, alpha=0.05, two.tailed=TRUE, n=15, rho2_trt=0.10, omega2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-pupr-036",
      "template": "individual_rct",
      "difficulty": "intermediate",
      "question": "An physical therapist is designing a individual-level randomized trial . The expected effect size is 0.15. At significance level of 0.05 with 80% power using a two-sided test, how many top-level units (e.g., schools, clinics) are needed?",
      "expected_template": "individual_rct",
      "ground_truth": {
        "n": 1397
      },
      "tolerance": {
        "n": 70
      },
      "source": {
        "package": "PowerUpR",
        "function": "mrss.ira",
        "origin": "PowerUpR::mrss.ira CRAN documentation",
        "variation": "ira_es15_p80"
      },
      "reference_code": "library(PowerUpR)\nmrss.ira(es=0.15, power=0.80, alpha=0.05, two.tailed=TRUE)",
      "tier": 3
    },
    {
      "id": "t3-pupr-037",
      "template": "cluster_rct_2level",
      "difficulty": "intermediate",
      "question": "An cardiologist is running a 2-level cluster randomized trial with 25 individuals per cluster. The expected effect size is 0.2. The ICC at level 2 is 0.15. What power will a two-sided test achieve at significance level of 0.05?",
      "expected_template": "cluster_rct_2level",
      "ground_truth": {
        "power": 0.2946
      },
      "tolerance": {
        "power": 0.01
      },
      "source": {
        "package": "PowerUpR",
        "function": "power.cra2",
        "origin": "PowerUpR::power.cra2 CRAN documentation",
        "variation": "power_cra2_cov"
      },
      "reference_code": "library(PowerUpR)\npower.cra2(es=0.20, alpha=0.05, two.tailed=TRUE, n=25, J=30, rho2=0.15, r22=0.30)",
      "tier": 3
    },
    {
      "id": "t3-sp-012",
      "template": "mixed_design",
      "difficulty": "intermediate",
      "question": "A gastroenterologist is conducting a mixed factorial study (2b*2w) with 40 participants per cell measuring fatigue severity scores with correlation 0.5 between repeated measures. What power does the study have for main effects and interactions at significance level of 0.05?",
      "expected_template": "mixed_design",
      "ground_truth": {
        "power_a": 0.2473,
        "power_b": 0.5981,
        "power_a_b": 0.5981
      },
      "tolerance": {
        "power_a": 0.02,
        "power_b": 0.0299,
        "power_a_b": 0.0299
      },
      "source": {
        "package": "Superpower",
        "function": "ANOVA_exact",
        "origin": "Superpower::ANOVA_exact CRAN documentation",
        "variation": "2b2w_n40_r05_interaction"
      },
      "reference_code": "library(Superpower)\n{ d <- ANOVA_design(design=\"2b*2w\", n=40, mu=c(0, 0.5, 0, 0), sd=1, r=0.5, plot=FALSE); ANOVA_exact(d, verbose=FALSE) }",
      "tier": 3
    },
    {
      "id": "t3-sp-013",
      "template": "mixed_design",
      "difficulty": "advanced",
      "question": "A pulmonologist is conducting a mixed factorial study (2b*3w) with 30 participants per cell measuring attention scores with correlation 0.5 between repeated measures. What power does the study have for main effects and interactions at significance level of 0.05?",
      "expected_template": "mixed_design",
      "ground_truth": {
        "power_a": 0.1541,
        "power_b": 0.7874,
        "power_a_b": 0.258
      },
      "tolerance": {
        "power_a": 0.02,
        "power_b": 0.0394,
        "power_a_b": 0.02
      },
      "source": {
        "package": "Superpower",
        "function": "ANOVA_exact",
        "origin": "Superpower::ANOVA_exact CRAN documentation",
        "variation": "2b3w_n30_r05_differential"
      },
      "reference_code": "library(Superpower)\n{ d <- ANOVA_design(design=\"2b*3w\", n=30, mu=c(0, 0.3, 0.6, 0, 0.1, 0.2), sd=1, r=0.5, plot=FALSE); ANOVA_exact(d, verbose=FALSE) }",
      "tier": 3
    },
    {
      "id": "t3-sp-014",
      "template": "mixed_design",
      "difficulty": "intermediate",
      "question": "A rheumatologist is conducting a mixed factorial study (2b*2w) with 60 participants per cell measuring motor function scores with correlation 0.5 between repeated measures. What power does the study have for main effects and interactions at significance level of 0.05?",
      "expected_template": "mixed_design",
      "ground_truth": {
        "power_a": 0.469,
        "power_b": 0.9031,
        "power_a_b": 0.05
      },
      "tolerance": {
        "power_a": 0.0234,
        "power_b": 0.0452,
        "power_a_b": 0.02
      },
      "source": {
        "package": "Superpower",
        "function": "ANOVA_exact",
        "origin": "Superpower::ANOVA_exact CRAN documentation",
        "variation": "2b2w_n60_additive"
      },
      "reference_code": "library(Superpower)\n{ d <- ANOVA_design(design=\"2b*2w\", n=60, mu=c(0, 0.3, 0.3, 0.6), sd=1, r=0.5, plot=FALSE); ANOVA_exact(d, verbose=FALSE) }",
      "tier": 3
    },
    {
      "id": "t3-sp-015",
      "template": "factorial_design",
      "difficulty": "advanced",
      "question": "A dermatologist has 50 participants per cell in a 2 x 2 x 2 factorial design studying symptom severity scores with cell means (0.0, 0.0, 0.0, 0.5, 0.0, 0.0, 0.0, 0.0) with SD = 1. What power is achieved for main effects and interactions at significance level of 0.05?",
      "expected_template": "factorial_design",
      "ground_truth": {
        "power_a": 0.2386,
        "power_b": 0.2386,
        "power_c": 0.2386,
        "power_a_b": 0.2386,
        "power_a_c": 0.2386,
        "power_b_c": 0.2386,
        "power_a_b_c": 0.2386
      },
      "tolerance": {
        "power_a": 0.02,
        "power_b": 0.02,
        "power_c": 0.02,
        "power_a_b": 0.02,
        "power_a_c": 0.02,
        "power_b_c": 0.02,
        "power_a_b_c": 0.02
      },
      "source": {
        "package": "Superpower",
        "function": "ANOVA_exact",
        "origin": "Superpower::ANOVA_exact CRAN documentation",
        "variation": "2x2x2b_n50_3way_int"
      },
      "reference_code": "library(Superpower)\n{ d <- ANOVA_design(design=\"2b*2b*2b\", n=50, mu=c(0, 0, 0, 0.5, 0, 0, 0, 0), sd=1, plot=FALSE); ANOVA_exact(d, verbose=FALSE) }",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-001",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A ophthalmologist is planning a fixed-sample clinical trial for type 2 diabetes. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 91
      },
      "tolerance": {
        "sample_size": 5
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d1_sd17_p80"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=1, sd=1.7, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-002",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A nephrologist is planning a fixed-sample clinical trial for major depressive disorder. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 126
      },
      "tolerance": {
        "sample_size": 7
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d05_sd1_p80"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=0.5, sd=1.0, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-003",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A infectious disease specialist is planning a fixed-sample clinical trial for chronic pain. At significance level of 0.05 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 126
      },
      "tolerance": {
        "sample_size": 7
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d1_sd2_2sided"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=1, sd=2.0, alpha=0.05, beta=0.20, sided=2)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-004",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A psychologist is planning a fixed-sample clinical trial for asthma. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 349
      },
      "tolerance": {
        "sample_size": 18
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d03_sd1"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=0.3, sd=1.0, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-005",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A educational researcher is planning a fixed-sample clinical trial for COPD. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 122
      },
      "tolerance": {
        "sample_size": 7
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d1_sd17_p90"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=1, sd=1.7, alpha=0.025, beta=0.10, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-006",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A epidemiologist is planning a fixed-sample clinical trial for rheumatoid arthritis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 423
      },
      "tolerance": {
        "sample_size": 22
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d03_2sided"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=0.3, sd=1.0, alpha=0.025, beta=0.20, sided=2)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-007",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A nurse researcher is planning a fixed-sample clinical trial for breast cancer. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 103
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d1_ratio2"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=1, sd=1.7, alpha=0.025, beta=0.20, ratio=2, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-008",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A social scientist is planning a fixed-sample clinical trial for heart failure. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 379
      },
      "tolerance": {
        "sample_size": 19
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d05_sd15_p90"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=0.5, sd=1.5, alpha=0.025, beta=0.10, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-009",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A pharmacist researcher is planning a fixed-sample clinical trial for Alzheimer's disease. At significance level of 0.01 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 953
      },
      "tolerance": {
        "sample_size": 48
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d025_alpha01_p90_2s"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=0.25, sd=1.0, alpha=0.01, beta=0.10, sided=2)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-010",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A gerontologist is planning a fixed-sample clinical trial for Parkinson's disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 262
      },
      "tolerance": {
        "sample_size": 14
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d2_sd5_ratio3"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=2, sd=5, alpha=0.025, beta=0.20, ratio=3, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-011",
      "template": "fixed_design",
      "difficulty": "advanced",
      "question": "A sports medicine physician is planning a fixed-sample clinical trial for multiple sclerosis. At significance level of 0.025 with 95% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 1300
      },
      "tolerance": {
        "sample_size": 65
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d01_sd05_p95"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=0.1, sd=0.5, alpha=0.025, beta=0.05, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nnormal-012",
      "template": "fixed_design",
      "difficulty": "advanced",
      "question": "A allergist is planning a fixed-sample clinical trial for chronic kidney disease. At significance level of 0.005 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 154
      },
      "tolerance": {
        "sample_size": 8
      },
      "source": {
        "package": "gsDesign",
        "function": "nNormal",
        "origin": "gsDesign::nNormal CRAN documentation",
        "variation": "nnorm_d1_alpha005_2s"
      },
      "reference_code": "library(gsDesign)\nnNormal(delta1=1, sd=1.7, alpha=0.005, beta=0.20, sided=2)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-013",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A urologist is planning a fixed-sample clinical trial for inflammatory bowel disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 1372
      },
      "tolerance": {
        "sample_size": 69
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_15v10_p80"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.15, p2=0.10, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-014",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A hematologist is planning a fixed-sample clinical trial for migraine. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 398
      },
      "tolerance": {
        "sample_size": 20
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_20v10_p80"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.20, p2=0.10, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-015",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A clinical nutritionist is planning a fixed-sample clinical trial for generalized anxiety disorder. At significance level of 0.05 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 775
      },
      "tolerance": {
        "sample_size": 39
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_50v40_2sided"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.50, p2=0.40, alpha=0.05, beta=0.20, sided=2)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-016",
      "template": "fixed_design",
      "difficulty": "basic",
      "question": "A rehabilitation specialist is planning a fixed-sample clinical trial for osteoarthritis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 500
      },
      "tolerance": {
        "sample_size": 25
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_25v15"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.25, p2=0.15, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-017",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A occupational therapist is planning a fixed-sample clinical trial for atrial fibrillation. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 784
      },
      "tolerance": {
        "sample_size": 40
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_30v20_p90"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.30, p2=0.20, alpha=0.025, beta=0.10, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-018",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A speech pathologist is planning a fixed-sample clinical trial for psoriasis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 1506
      },
      "tolerance": {
        "sample_size": 76
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_15v10_ratio2"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.15, p2=0.10, alpha=0.025, beta=0.20, ratio=2, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-019",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A physical therapist is planning a fixed-sample clinical trial for epilepsy. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 953
      },
      "tolerance": {
        "sample_size": 48
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_40v30_p90"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.40, p2=0.30, alpha=0.025, beta=0.10, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-020",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A cardiologist is planning a fixed-sample clinical trial for hypertension. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 869
      },
      "tolerance": {
        "sample_size": 44
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_10v05"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.10, p2=0.05, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-021",
      "template": "fixed_design",
      "difficulty": "intermediate",
      "question": "A oncologist is planning a fixed-sample clinical trial for type 2 diabetes. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 874
      },
      "tolerance": {
        "sample_size": 44
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_60v50_ratio2"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.60, p2=0.50, alpha=0.025, beta=0.20, ratio=2, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-022",
      "template": "fixed_design",
      "difficulty": "advanced",
      "question": "A neurologist is planning a fixed-sample clinical trial for major depressive disorder. At significance level of 0.01 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 2599
      },
      "tolerance": {
        "sample_size": 130
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_15v10_alpha01_2s_p90"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.15, p2=0.10, alpha=0.01, beta=0.10, sided=2)",
      "tier": 3
    },
    {
      "id": "t3-gs-nbinomial-023",
      "template": "fixed_design",
      "difficulty": "advanced",
      "question": "A psychiatrist is planning a fixed-sample clinical trial for chronic pain. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design",
      "ground_truth": {
        "sample_size": 498
      },
      "tolerance": {
        "sample_size": 25
      },
      "source": {
        "package": "gsDesign",
        "function": "nBinomial",
        "origin": "gsDesign::nBinomial CRAN documentation",
        "variation": "nbin_20v10_ratio3"
      },
      "reference_code": "library(gsDesign)\nnBinomial(p1=0.20, p2=0.10, alpha=0.025, beta=0.20, ratio=3, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-024",
      "template": "fixed_design_survival",
      "difficulty": "intermediate",
      "question": "A pediatrician is planning a fixed-sample clinical trial for a time-to-event endpoint for asthma. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 289,
        "events": 191
      },
      "tolerance": {
        "total_sample_size": 15,
        "events": 10
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med12v18_p80"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/12, lambda2=log(2)/18, eta=0, Ts=36, Tr=24, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-025",
      "template": "fixed_design_survival",
      "difficulty": "intermediate",
      "question": "A endocrinologist is planning a fixed-sample clinical trial for a time-to-event endpoint for COPD. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 289,
        "events": 191
      },
      "tolerance": {
        "total_sample_size": 15,
        "events": 10
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med10v15_p80"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/10, lambda2=log(2)/15, eta=0, Ts=30, Tr=20, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-026",
      "template": "fixed_design_survival",
      "difficulty": "intermediate",
      "question": "A orthopedic surgeon is planning a fixed-sample clinical trial for a time-to-event endpoint for rheumatoid arthritis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 302,
        "events": 191
      },
      "tolerance": {
        "total_sample_size": 16,
        "events": 10
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med8v12_p80"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/8, lambda2=log(2)/12, eta=0, Ts=24, Tr=18, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-027",
      "template": "fixed_design_survival",
      "difficulty": "intermediate",
      "question": "A gastroenterologist is planning a fixed-sample clinical trial for a time-to-event endpoint for breast cancer. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 237,
        "events": 190
      },
      "tolerance": {
        "total_sample_size": 12,
        "events": 10
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med6v9_p80"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/6, lambda2=log(2)/9, eta=0, Ts=24, Tr=12, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-028",
      "template": "fixed_design_survival",
      "difficulty": "advanced",
      "question": "A pulmonologist is planning a fixed-sample clinical trial for a time-to-event endpoint for heart failure. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 387,
        "events": 255
      },
      "tolerance": {
        "total_sample_size": 20,
        "events": 13
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med12v18_p90"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/12, lambda2=log(2)/18, eta=0, Ts=36, Tr=24, alpha=0.025, beta=0.10, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-029",
      "template": "fixed_design_survival",
      "difficulty": "advanced",
      "question": "A rheumatologist is planning a fixed-sample clinical trial for a time-to-event endpoint for Alzheimer's disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 318,
        "events": 191
      },
      "tolerance": {
        "total_sample_size": 16,
        "events": 10
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med12v18_dropout"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/12, lambda2=log(2)/18, eta=0.01, Ts=36, Tr=24, alpha=0.025, beta=0.20, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-030",
      "template": "fixed_design_survival",
      "difficulty": "advanced",
      "question": "A dermatologist is planning a fixed-sample clinical trial for a time-to-event endpoint for Parkinson's disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 330,
        "events": 210
      },
      "tolerance": {
        "total_sample_size": 17,
        "events": 11
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med12v18_ratio2"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/12, lambda2=log(2)/18, eta=0, Ts=36, Tr=24, alpha=0.025, beta=0.20, ratio=2, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-nsurvival-031",
      "template": "fixed_design_survival",
      "difficulty": "advanced",
      "question": "A ophthalmologist is planning a fixed-sample clinical trial for a time-to-event endpoint for multiple sclerosis. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "fixed_design_survival",
      "ground_truth": {
        "total_sample_size": 297,
        "events": 190
      },
      "tolerance": {
        "total_sample_size": 15,
        "events": 10
      },
      "source": {
        "package": "gsDesign",
        "function": "nSurvival",
        "origin": "gsDesign::nSurvival CRAN documentation",
        "variation": "nsurv_med15v24_p90"
      },
      "reference_code": "library(gsDesign)\nnSurvival(lambda1=log(2)/15, lambda2=log(2)/24, eta=0, Ts=48, Tr=36, alpha=0.025, beta=0.10, sided=1)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-032",
      "template": "group_sequential",
      "difficulty": "intermediate",
      "question": "A nephrologist is planning a group sequential design with 2 analyses for chronic kidney disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0037,
        "inflation_factor": 1.0037,
        "analyses": 2,
        "upper_bounds": [
          2.9626,
          1.9686
        ],
        "power": 0.8,
        "alpha": 0.025
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_2look_1sided_LDOF"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=2, test.type=1, alpha=0.025, beta=0.20, sfu=sfLDOF)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-033",
      "template": "group_sequential",
      "difficulty": "intermediate",
      "question": "A infectious disease specialist is planning a group sequential design with 2 analyses for inflammatory bowel disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.1226,
        "inflation_factor": 1.1226,
        "analyses": 2,
        "upper_bounds": [
          2.157,
          2.201
        ],
        "power": 0.8,
        "alpha": 0.025
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_2look_1sided_Pocock"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=2, test.type=1, alpha=0.025, beta=0.20, sfu=sfLDPocock)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-034",
      "template": "group_sequential",
      "difficulty": "intermediate",
      "question": "A psychologist is planning a group sequential design with 3 analyses for migraine. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0128,
        "inflation_factor": 1.0128,
        "analyses": 3,
        "upper_bounds": [
          3.7103,
          2.5114,
          1.993
        ],
        "power": 0.8,
        "alpha": 0.025
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_3look_1sided_LDOF"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=3, test.type=1, alpha=0.025, beta=0.20, sfu=sfLDOF)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-035",
      "template": "group_sequential",
      "difficulty": "intermediate",
      "question": "A educational researcher is planning a group sequential design with 3 analyses for generalized anxiety disorder. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.1704,
        "inflation_factor": 1.1704,
        "analyses": 3,
        "upper_bounds": [
          2.2794,
          2.2949,
          2.2959
        ],
        "power": 0.8,
        "alpha": 0.025
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_3look_1sided_Pocock"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=3, test.type=1, alpha=0.025, beta=0.20, sfu=sfLDPocock)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-036",
      "template": "group_sequential",
      "difficulty": "intermediate",
      "question": "A epidemiologist is planning a group sequential design with 3 analyses for osteoarthritis. At significance level of 0.05 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0203,
        "inflation_factor": 1.0203,
        "analyses": 3,
        "upper_bounds": [
          3.2001,
          2.1408,
          1.6948
        ],
        "power": 0.8,
        "alpha": 0.05,
        "lower_bounds": [
          -3.2001,
          -2.1408,
          -1.6948
        ]
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_3look_2sided_LDOF"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=3, test.type=2, alpha=0.05, beta=0.20, sfu=sfLDOF)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-037",
      "template": "group_sequential",
      "difficulty": "advanced",
      "question": "A nurse researcher is planning a group sequential design with 3 analyses for atrial fibrillation. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0699,
        "inflation_factor": 1.0699,
        "analyses": 3,
        "upper_bounds": [
          3.0107,
          2.5465,
          1.9992
        ],
        "power": 0.9,
        "alpha": 0.025,
        "lower_bounds": [
          -0.2387,
          0.9411,
          1.9992
        ]
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.027,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_3look_HSD_futility_p90"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=3, test.type=4, alpha=0.025, beta=0.10, sfu=sfHSD, sfupar=-4, sfl=sfHSD, sflpar=-2)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-038",
      "template": "group_sequential",
      "difficulty": "advanced",
      "question": "A social scientist is planning a group sequential design with 3 analyses for psoriasis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0413,
        "inflation_factor": 1.0413,
        "analyses": 3,
        "upper_bounds": [
          3.7103,
          2.5111,
          1.9584
        ],
        "power": 0.8,
        "alpha": 0.025,
        "lower_bounds": [
          -0.2352,
          0.8959,
          1.9584
        ]
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_3look_nonbind_futility"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=3, test.type=3, alpha=0.025, beta=0.20, sfu=sfLDOF, sfl=sfHSD, sflpar=-2)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-039",
      "template": "group_sequential",
      "difficulty": "advanced",
      "question": "A pharmacist researcher is planning a group sequential design with 4 analyses for epilepsy. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0399,
        "inflation_factor": 1.0399,
        "analyses": 4,
        "upper_bounds": [
          4.3326,
          2.9631,
          2.359,
          2.0141
        ],
        "power": 0.8,
        "alpha": 0.025,
        "lower_bounds": [
          -1.0602,
          -0.0249,
          0.9514,
          2.0141
        ]
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_4look_bind_futility"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=4, test.type=4, alpha=0.025, beta=0.20, sfu=sfLDOF, sfl=sfHSD, sflpar=-4)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-040",
      "template": "group_sequential",
      "difficulty": "advanced",
      "question": "A gerontologist is planning a group sequential design with 2 analyses for hypertension. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0423,
        "inflation_factor": 1.0423,
        "analyses": 2,
        "upper_bounds": [
          2.75,
          1.9811
        ],
        "power": 0.8,
        "alpha": 0.025,
        "lower_bounds": [
          0.4133,
          1.9811
        ]
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_2look_HSD_bind_futility"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=2, test.type=4, alpha=0.025, beta=0.20, sfu=sfHSD, sfupar=-4, sfl=sfHSD, sflpar=-2)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-041",
      "template": "group_sequential",
      "difficulty": "advanced",
      "question": "A sports medicine physician is planning a group sequential design with 5 analyses for type 2 diabetes. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0247,
        "inflation_factor": 1.0247,
        "analyses": 5,
        "upper_bounds": [
          4.8769,
          3.357,
          2.6803,
          2.2898,
          2.031
        ],
        "power": 0.8,
        "alpha": 0.025
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_5look_LDOF"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=5, test.type=1, alpha=0.025, beta=0.20, sfu=sfLDOF)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-042",
      "template": "group_sequential",
      "difficulty": "advanced",
      "question": "A allergist is planning a group sequential design with 3 analyses for major depressive disorder. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.1364,
        "inflation_factor": 1.1364,
        "analyses": 3,
        "upper_bounds": [
          2.6775,
          2.3854,
          2.0637
        ],
        "power": 0.8,
        "alpha": 0.025,
        "lower_bounds": [
          0.0399,
          1.1028,
          2.0637
        ]
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.024,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_3look_HSD_m2_m1"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=3, test.type=4, alpha=0.025, beta=0.20, sfu=sfHSD, sfupar=-2, sfl=sfHSD, sflpar=-1)",
      "tier": 3
    },
    {
      "id": "t3-gs-gsdesign-043",
      "template": "group_sequential",
      "difficulty": "advanced",
      "question": "A urologist is planning a group sequential design with 3 analyses for chronic pain. At significance level of 0.01 with 90% power, what maximum sample size is required?",
      "expected_template": "group_sequential",
      "ground_truth": {
        "n_fix": 1,
        "max_info_ratio": 1.0067,
        "inflation_factor": 1.0067,
        "analyses": 3,
        "upper_bounds": [
          4.3106,
          2.9472,
          2.3461
        ],
        "power": 0.9,
        "alpha": 0.01
      },
      "tolerance": {
        "n_fix": 2,
        "max_info_ratio": 2,
        "inflation_factor": 2,
        "analyses": 2,
        "power": 0.027,
        "alpha": 0.01
      },
      "source": {
        "package": "gsDesign",
        "function": "gsDesign",
        "origin": "gsDesign::gsDesign CRAN documentation",
        "variation": "gsd_3look_alpha01_p90"
      },
      "reference_code": "library(gsDesign)\ngsDesign(k=3, test.type=1, alpha=0.01, beta=0.10, sfu=sfLDOF)",
      "tier": 3
    },
    {
      "id": "t3-ptost-001",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.1. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 8,
        "power": 0.9155
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0275
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv10_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.10, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-002",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.15. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 12,
        "power": 0.8305
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0249
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv15_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.15, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-003",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 20,
        "power": 0.8347
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.025
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv20_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.20, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-004",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 28,
        "power": 0.8074
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv25_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-005",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 40,
        "power": 0.8158
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv30_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.30, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-006",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.35. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 52,
        "power": 0.8075
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv35_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.35, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-007",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 66,
        "power": 0.8053
      },
      "tolerance": {
        "sample_size": 4,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv40_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-008",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 26,
        "power": 0.9176
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0275
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv20_p90"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.90, CV=0.20, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-009",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 38,
        "power": 0.9089
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0273
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv25_p90"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.90, CV=0.25, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-010",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 52,
        "power": 0.902
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0271
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv30_p90"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.90, CV=0.30, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-011",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.85. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 206,
        "power": 0.8011
      },
      "tolerance": {
        "sample_size": 11,
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv25_t085"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=0.85, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-012",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 56,
        "power": 0.8036
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv25_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=0.90, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-013",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 1.0. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 24,
        "power": 0.8372
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0251
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv25_t100"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=1.00, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-014",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 1.05. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 28,
        "power": 0.8163
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x2_cv25_t105"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=1.05, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-015",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a parallel crossover design. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 36,
        "power": 0.8099
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0243
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_parallel_cv20"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.20, theta0=0.95, design=\"parallel\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-016",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a parallel crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 54,
        "power": 0.8039
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_parallel_cv25"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=0.95, design=\"parallel\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-017",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a parallel crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 76,
        "power": 0.8031
      },
      "tolerance": {
        "sample_size": 4,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_parallel_cv30"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.30, theta0=0.95, design=\"parallel\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-018",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a parallel crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 130,
        "power": 0.8035
      },
      "tolerance": {
        "sample_size": 7,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_parallel_cv40"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"parallel\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-019",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2x3 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.8204
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_223_cv30"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.30, theta0=0.95, design=\"2x2x3\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-020",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2x3 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 50,
        "power": 0.8119
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0244
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_223_cv40"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"2x2x3\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-021",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 20,
        "power": 0.8202
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_224_cv30"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.30, theta0=0.95, design=\"2x2x4\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-022",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 34,
        "power": 0.8193
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_224_cv40"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"2x2x4\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-023",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.8204
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_233_cv30"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.30, theta0=0.95, design=\"2x3x3\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-024",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 51,
        "power": 0.8194
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_233_cv40"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"2x3x3\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-025",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 20 participants per group. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8347
      },
      "tolerance": {
        "power": 0.025
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n20_cv20_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=20, CV=0.20, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-026",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 24 participants per group. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.896
      },
      "tolerance": {
        "power": 0.0269
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n24_cv20_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=24, CV=0.20, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-027",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 26 participants per group. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.7761
      },
      "tolerance": {
        "power": 0.0233
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n26_cv25_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=26, CV=0.25, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-028",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 30 participants per group. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8343
      },
      "tolerance": {
        "power": 0.025
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n30_cv25_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=30, CV=0.25, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-029",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 36 participants per group. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8941
      },
      "tolerance": {
        "power": 0.0268
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n36_cv25_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=36, CV=0.25, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-030",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 40 participants per group. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8158
      },
      "tolerance": {
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n40_cv30_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=40, CV=0.30, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-031",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 48 participants per group. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.879
      },
      "tolerance": {
        "power": 0.0264
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n48_cv30_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=48, CV=0.30, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-032",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 60 participants per group. The within-subject coefficient of variation (CV) is 0.35. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8593
      },
      "tolerance": {
        "power": 0.0258
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n60_cv35_t095"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=60, CV=0.35, theta0=0.95, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-033",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 24 participants per group. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.6373
      },
      "tolerance": {
        "power": 0.0191
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n24_cv20_t090"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=24, CV=0.20, theta0=0.90, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-034",
      "template": "bioequivalence_tost",
      "difficulty": "basic",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 36 participants per group. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 1.0. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8702
      },
      "tolerance": {
        "power": 0.0261
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2_n36_cv30_t100"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=36, CV=0.30, theta0=1.00, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-035",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A average bioequivalence (TOST) study uses a parallel crossover design with 40 participants per group. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8492
      },
      "tolerance": {
        "power": 0.0255
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_parallel_n40_cv20"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=40, CV=0.20, theta0=0.95, design=\"parallel\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-036",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A average bioequivalence (TOST) study uses a 2x2x4 crossover design with 24 participants per group. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8819
      },
      "tolerance": {
        "power": 0.0265
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x2x4_n24_cv30"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=24, CV=0.30, theta0=0.95, design=\"2x2x4\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-037",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A average bioequivalence (TOST) study uses a 2x3x3 crossover design with 30 participants per group. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "power": 0.8204
      },
      "tolerance": {
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.TOST",
        "origin": "PowerTOST::power.TOST CRAN docs / direct computation",
        "variation": "power_2x3x3_n30_cv30"
      },
      "reference_code": "library(PowerTOST)\npower.TOST(alpha=0.05, n=30, CV=0.30, theta0=0.95, design=\"2x3x3\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-038",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 54,
        "power": 0.8159
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_233_cv30_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.30, theta0=0.90, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-039",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 42,
        "power": 0.8006
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_233_cv40_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.90, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-040",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 39,
        "power": 0.8076
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_233_cv50_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.50, theta0=0.90, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-041",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.6. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 48,
        "power": 0.8176
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_233_cv60_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.60, theta0=0.90, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-042",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 27,
        "power": 0.8004
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_233_cv40_t095"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-043",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.826
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0248
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_233_cv50_t095"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.50, theta0=0.95, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-044",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.8066
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_224_cv40_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.90, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-045",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 28,
        "power": 0.8143
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0244
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_224_cv50_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.50, theta0=0.90, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-046",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.45. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 20,
        "power": 0.8175
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.scABEL",
        "origin": "PowerTOST::sampleN.scABEL CRAN docs / direct computation",
        "variation": "scabel_224_cv45_t095"
      },
      "reference_code": "library(PowerTOST)\nsampleN.scABEL(alpha=0.05, targetpower=0.80, CV=0.45, theta0=0.95, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-047",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x3x3 crossover design with 36 participants per group. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.7452
      },
      "tolerance": {
        "power": 0.0224
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.scABEL",
        "origin": "PowerTOST::power.scABEL CRAN docs / direct computation",
        "variation": "pscabel_233_n36_cv40"
      },
      "reference_code": "library(PowerTOST)\npower.scABEL(alpha=0.05, n=36, CV=0.40, theta0=0.90, design=\"2x3x3\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-048",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x3x3 crossover design with 42 participants per group. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.8006
      },
      "tolerance": {
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.scABEL",
        "origin": "PowerTOST::power.scABEL CRAN docs / direct computation",
        "variation": "pscabel_233_n42_cv40"
      },
      "reference_code": "library(PowerTOST)\npower.scABEL(alpha=0.05, n=42, CV=0.40, theta0=0.90, design=\"2x3x3\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-049",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x3x3 crossover design with 48 participants per group. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.8784
      },
      "tolerance": {
        "power": 0.0264
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.scABEL",
        "origin": "PowerTOST::power.scABEL CRAN docs / direct computation",
        "variation": "pscabel_233_n48_cv50"
      },
      "reference_code": "library(PowerTOST)\npower.scABEL(alpha=0.05, n=48, CV=0.50, theta0=0.90, design=\"2x3x3\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-050",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x2x4 crossover design with 36 participants per group. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.863
      },
      "tolerance": {
        "power": 0.0259
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.scABEL",
        "origin": "PowerTOST::power.scABEL CRAN docs / direct computation",
        "variation": "pscabel_224_n36_cv40"
      },
      "reference_code": "library(PowerTOST)\npower.scABEL(alpha=0.05, n=36, CV=0.40, theta0=0.90, design=\"2x2x4\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-051",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 33,
        "power": 0.8084
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0243
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RSABE",
        "origin": "PowerTOST::sampleN.RSABE CRAN docs / direct computation",
        "variation": "rsabe_233_cv40_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RSABE(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.90, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-052",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.8023
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RSABE",
        "origin": "PowerTOST::sampleN.RSABE CRAN docs / direct computation",
        "variation": "rsabe_233_cv50_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RSABE(alpha=0.05, targetpower=0.80, CV=0.50, theta0=0.90, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-053",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.6. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 33,
        "power": 0.8171
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RSABE",
        "origin": "PowerTOST::sampleN.RSABE CRAN docs / direct computation",
        "variation": "rsabe_233_cv60_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RSABE(alpha=0.05, targetpower=0.80, CV=0.60, theta0=0.90, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-054",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x3x3 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 24,
        "power": 0.8086
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0243
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RSABE",
        "origin": "PowerTOST::sampleN.RSABE CRAN docs / direct computation",
        "variation": "rsabe_233_cv40_t095"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RSABE(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"2x3x3\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-055",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 24,
        "power": 0.8052
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RSABE",
        "origin": "PowerTOST::sampleN.RSABE CRAN docs / direct computation",
        "variation": "rsabe_224_cv40_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RSABE(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.90, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-056",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a reference-scaled average bioequivalence (RSABE) study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "sample_size": 22,
        "power": 0.8027
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RSABE",
        "origin": "PowerTOST::sampleN.RSABE CRAN docs / direct computation",
        "variation": "rsabe_224_cv50_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RSABE(alpha=0.05, targetpower=0.80, CV=0.50, theta0=0.90, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-057",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x3x3 crossover design with 30 participants per group. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.7729
      },
      "tolerance": {
        "power": 0.0232
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.RSABE",
        "origin": "PowerTOST::power.RSABE CRAN docs / direct computation",
        "variation": "prsabe_233_n30_cv40"
      },
      "reference_code": "library(PowerTOST)\npower.RSABE(alpha=0.05, n=30, CV=0.40, theta0=0.90, design=\"2x3x3\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-058",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x3x3 crossover design with 42 participants per group. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.8842
      },
      "tolerance": {
        "power": 0.0265
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.RSABE",
        "origin": "PowerTOST::power.RSABE CRAN docs / direct computation",
        "variation": "prsabe_233_n42_cv40"
      },
      "reference_code": "library(PowerTOST)\npower.RSABE(alpha=0.05, n=42, CV=0.40, theta0=0.90, design=\"2x3x3\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-059",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x3x3 crossover design with 42 participants per group. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.8897
      },
      "tolerance": {
        "power": 0.0267
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.RSABE",
        "origin": "PowerTOST::power.RSABE CRAN docs / direct computation",
        "variation": "prsabe_233_n42_cv50"
      },
      "reference_code": "library(PowerTOST)\npower.RSABE(alpha=0.05, n=42, CV=0.50, theta0=0.90, design=\"2x3x3\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-060",
      "template": "bioequivalence_scaled",
      "difficulty": "advanced",
      "question": "A reference-scaled average bioequivalence (RSABE) study uses a 2x2x4 crossover design with 36 participants per group. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_scaled",
      "ground_truth": {
        "power": 0.9226
      },
      "tolerance": {
        "power": 0.0277
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.RSABE",
        "origin": "PowerTOST::power.RSABE CRAN docs / direct computation",
        "variation": "prsabe_224_n36_cv40"
      },
      "reference_code": "library(PowerTOST)\npower.RSABE(alpha=0.05, n=36, CV=0.40, theta0=0.90, design=\"2x2x4\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-061",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A neurologist is designing a non-inferiority trial for major depressive disorder using the primary endpoint. The non-inferiority margin is 0.8. At significance level of 0.025 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "sample_size": 24,
        "power": 0.8193
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.noninf",
        "origin": "PowerTOST::sampleN.noninf CRAN docs / direct computation",
        "variation": "noninf_a025_cv20_t095_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.noninf(alpha=0.025, targetpower=0.80, margin=0.80, logscale=TRUE, CV=0.20, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-062",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A psychiatrist is designing a non-inferiority trial for chronic pain using the primary endpoint. The non-inferiority margin is 0.8. At significance level of 0.025 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "sample_size": 36,
        "power": 0.8203
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.noninf",
        "origin": "PowerTOST::sampleN.noninf CRAN docs / direct computation",
        "variation": "noninf_a025_cv25_t095_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.noninf(alpha=0.025, targetpower=0.80, margin=0.80, logscale=TRUE, CV=0.25, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-063",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A pediatrician is designing a non-inferiority trial for asthma using the primary endpoint. The non-inferiority margin is 0.8. At significance level of 0.025 with 90% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.9003
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.027
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.noninf",
        "origin": "PowerTOST::sampleN.noninf CRAN docs / direct computation",
        "variation": "noninf_a025_cv20_t095_p90"
      },
      "reference_code": "library(PowerTOST)\nsampleN.noninf(alpha=0.025, targetpower=0.90, margin=0.80, logscale=TRUE, CV=0.20, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-064",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A endocrinologist is designing a non-inferiority trial for COPD using the primary endpoint. The non-inferiority margin is 0.8. At significance level of 0.025 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "sample_size": 48,
        "power": 0.8017
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.noninf",
        "origin": "PowerTOST::sampleN.noninf CRAN docs / direct computation",
        "variation": "noninf_a025_cv30_t095_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.noninf(alpha=0.025, targetpower=0.80, margin=0.80, logscale=TRUE, CV=0.30, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-065",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A orthopedic surgeon is designing a non-inferiority trial for rheumatoid arthritis using the primary endpoint. The non-inferiority margin is 0.8. At significance level of 0.025 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "sample_size": 48,
        "power": 0.8139
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0244
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.noninf",
        "origin": "PowerTOST::sampleN.noninf CRAN docs / direct computation",
        "variation": "noninf_a025_cv20_t090_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.noninf(alpha=0.025, targetpower=0.80, margin=0.80, logscale=TRUE, CV=0.20, theta0=0.90, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-066",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A gastroenterologist is designing a non-inferiority trial for breast cancer using the primary endpoint. The non-inferiority margin is 0.8. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "sample_size": 18,
        "power": 0.8012
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.noninf",
        "origin": "PowerTOST::sampleN.noninf CRAN docs / direct computation",
        "variation": "noninf_a050_cv20_t095_p80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.noninf(alpha=0.050, targetpower=0.80, margin=0.80, logscale=TRUE, CV=0.20, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-067",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A pulmonologist is designing a non-inferiority trial for heart failure using the primary endpoint. The non-inferiority margin is 0.8. At significance level of 0.025 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "sample_size": 68,
        "power": 0.8094
      },
      "tolerance": {
        "sample_size": 4,
        "power": 0.0243
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.noninf",
        "origin": "PowerTOST::sampleN.noninf CRAN docs / direct computation",
        "variation": "noninf_parallel_cv25"
      },
      "reference_code": "library(PowerTOST)\nsampleN.noninf(alpha=0.025, targetpower=0.80, margin=0.80, logscale=TRUE, CV=0.25, theta0=0.95, design=\"parallel\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-068",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A rheumatologist has 24 participants per group for a non-inferiority trial using the primary endpoint. The non-inferiority margin is 0.8. What power is achieved at significance level of 0.025?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "power": 0.8193
      },
      "tolerance": {
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.noninf",
        "origin": "PowerTOST::power.noninf CRAN docs / direct computation",
        "variation": "pnoninf_n24_cv20"
      },
      "reference_code": "library(PowerTOST)\npower.noninf(alpha=0.025, n=24, CV=0.20, theta0=0.95, margin=0.80, logscale=TRUE, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-069",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A dermatologist has 30 participants per group for a non-inferiority trial using the primary endpoint. The non-inferiority margin is 0.8. What power is achieved at significance level of 0.025?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "power": 0.742
      },
      "tolerance": {
        "power": 0.0223
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.noninf",
        "origin": "PowerTOST::power.noninf CRAN docs / direct computation",
        "variation": "pnoninf_n30_cv25"
      },
      "reference_code": "library(PowerTOST)\npower.noninf(alpha=0.025, n=30, CV=0.25, theta0=0.95, margin=0.80, logscale=TRUE, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-070",
      "template": "non_inferiority",
      "difficulty": "intermediate",
      "question": "A ophthalmologist has 40 participants per group for a non-inferiority trial using the primary endpoint. The non-inferiority margin is 0.8. What power is achieved at significance level of 0.025?",
      "expected_template": "non_inferiority",
      "ground_truth": {
        "power": 0.7229
      },
      "tolerance": {
        "power": 0.0217
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.noninf",
        "origin": "PowerTOST::power.noninf CRAN docs / direct computation",
        "variation": "pnoninf_n40_cv30"
      },
      "reference_code": "library(PowerTOST)\npower.noninf(alpha=0.025, n=40, CV=0.30, theta0=0.95, margin=0.80, logscale=TRUE, design=\"2x2\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-071",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.05. The expected geometric mean ratio (test/reference) is 0.975. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "sample_size": 32,
        "power": 0.8081
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.NTID",
        "origin": "PowerTOST::sampleN.NTID CRAN docs / direct computation",
        "variation": "ntid_cv05_t0975"
      },
      "reference_code": "library(PowerTOST)\nsampleN.NTID(alpha=0.05, targetpower=0.80, CV=0.05, theta0=0.975, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-072",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.1. The expected geometric mean ratio (test/reference) is 0.975. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "sample_size": 18,
        "power": 0.8418
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0253
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.NTID",
        "origin": "PowerTOST::sampleN.NTID CRAN docs / direct computation",
        "variation": "ntid_cv10_t0975"
      },
      "reference_code": "library(PowerTOST)\nsampleN.NTID(alpha=0.05, targetpower=0.80, CV=0.10, theta0=0.975, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-073",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.15. The expected geometric mean ratio (test/reference) is 0.975. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "sample_size": 16,
        "power": 0.8415
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0252
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.NTID",
        "origin": "PowerTOST::sampleN.NTID CRAN docs / direct computation",
        "variation": "ntid_cv15_t0975"
      },
      "reference_code": "library(PowerTOST)\nsampleN.NTID(alpha=0.05, targetpower=0.80, CV=0.15, theta0=0.975, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-074",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.1. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "sample_size": 34,
        "power": 0.8184
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.NTID",
        "origin": "PowerTOST::sampleN.NTID CRAN docs / direct computation",
        "variation": "ntid_cv10_t0950"
      },
      "reference_code": "library(PowerTOST)\nsampleN.NTID(alpha=0.05, targetpower=0.80, CV=0.10, theta0=0.950, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-075",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.1. The expected geometric mean ratio (test/reference) is 1.0. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "sample_size": 14,
        "power": 0.8158
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.NTID",
        "origin": "PowerTOST::sampleN.NTID CRAN docs / direct computation",
        "variation": "ntid_cv10_t1000"
      },
      "reference_code": "library(PowerTOST)\nsampleN.NTID(alpha=0.05, targetpower=0.80, CV=0.10, theta0=1.000, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-076",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A narrow therapeutic index drug (NTID) bioequivalence study uses a 2x2x4 crossover design with 18 participants per group. The within-subject coefficient of variation (CV) is 0.1. The expected geometric mean ratio (test/reference) is 0.975. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "power": 0.8418
      },
      "tolerance": {
        "power": 0.0253
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.NTID",
        "origin": "PowerTOST::power.NTID CRAN docs / direct computation",
        "variation": "pntid_n18_cv10"
      },
      "reference_code": "library(PowerTOST)\npower.NTID(alpha=0.05, n=18, CV=0.10, theta0=0.975, design=\"2x2x4\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-077",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A narrow therapeutic index drug (NTID) bioequivalence study uses a 2x2x4 crossover design with 24 participants per group. The within-subject coefficient of variation (CV) is 0.1. The expected geometric mean ratio (test/reference) is 0.975. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "power": 0.9323
      },
      "tolerance": {
        "power": 0.028
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.NTID",
        "origin": "PowerTOST::power.NTID CRAN docs / direct computation",
        "variation": "pntid_n24_cv10"
      },
      "reference_code": "library(PowerTOST)\npower.NTID(alpha=0.05, n=24, CV=0.10, theta0=0.975, design=\"2x2x4\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-078",
      "template": "bioequivalence_ntid",
      "difficulty": "advanced",
      "question": "A narrow therapeutic index drug (NTID) bioequivalence study uses a 2x2x4 crossover design with 16 participants per group. The within-subject coefficient of variation (CV) is 0.05. The expected geometric mean ratio (test/reference) is 0.975. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_ntid",
      "ground_truth": {
        "power": 0.5286
      },
      "tolerance": {
        "power": 0.0159
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.NTID",
        "origin": "PowerTOST::power.NTID CRAN docs / direct computation",
        "variation": "pntid_n16_cv05"
      },
      "reference_code": "library(PowerTOST)\npower.NTID(alpha=0.05, n=16, CV=0.05, theta0=0.975, design=\"2x2x4\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-079",
      "template": "bioequivalence_hvntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_hvntid",
      "ground_truth": {
        "sample_size": 22,
        "power": 0.8297
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0249
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.HVNTID",
        "origin": "PowerTOST::sampleN.HVNTID CRAN docs / direct computation",
        "variation": "hvntid_cv30_t095"
      },
      "reference_code": "library(PowerTOST)\nsampleN.HVNTID(alpha=0.05, targetpower=0.80, CV=0.30, theta0=0.95, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-080",
      "template": "bioequivalence_hvntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_hvntid",
      "ground_truth": {
        "sample_size": 34,
        "power": 0.8073
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.HVNTID",
        "origin": "PowerTOST::sampleN.HVNTID CRAN docs / direct computation",
        "variation": "hvntid_cv40_t095"
      },
      "reference_code": "library(PowerTOST)\nsampleN.HVNTID(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.95, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-081",
      "template": "bioequivalence_hvntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_hvntid",
      "ground_truth": {
        "sample_size": 50,
        "power": 0.805
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.HVNTID",
        "origin": "PowerTOST::sampleN.HVNTID CRAN docs / direct computation",
        "variation": "hvntid_cv50_t095"
      },
      "reference_code": "library(PowerTOST)\nsampleN.HVNTID(alpha=0.05, targetpower=0.80, CV=0.50, theta0=0.95, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-082",
      "template": "bioequivalence_hvntid",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a narrow therapeutic index drug (NTID) bioequivalence study using a 2x2x4 crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_hvntid",
      "ground_truth": {
        "sample_size": 68,
        "power": 0.8024
      },
      "tolerance": {
        "sample_size": 4,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.HVNTID",
        "origin": "PowerTOST::sampleN.HVNTID CRAN docs / direct computation",
        "variation": "hvntid_cv40_t090"
      },
      "reference_code": "library(PowerTOST)\nsampleN.HVNTID(alpha=0.05, targetpower=0.80, CV=0.40, theta0=0.90, design=\"2x2x4\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-083",
      "template": "bioequivalence_hvntid",
      "difficulty": "advanced",
      "question": "A narrow therapeutic index drug (NTID) bioequivalence study uses a 2x2x4 crossover design with 34 participants per group. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_hvntid",
      "ground_truth": {
        "power": 0.8073
      },
      "tolerance": {
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.HVNTID",
        "origin": "PowerTOST::power.HVNTID CRAN docs / direct computation",
        "variation": "phvntid_n34_cv40"
      },
      "reference_code": "library(PowerTOST)\npower.HVNTID(alpha=0.05, n=34, CV=0.40, theta0=0.95, design=\"2x2x4\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-084",
      "template": "bioequivalence_hvntid",
      "difficulty": "advanced",
      "question": "A narrow therapeutic index drug (NTID) bioequivalence study uses a 2x2x4 crossover design with 40 participants per group. The within-subject coefficient of variation (CV) is 0.5. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_hvntid",
      "ground_truth": {
        "power": 0.7076
      },
      "tolerance": {
        "power": 0.0212
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.HVNTID",
        "origin": "PowerTOST::power.HVNTID CRAN docs / direct computation",
        "variation": "phvntid_n40_cv50"
      },
      "reference_code": "library(PowerTOST)\npower.HVNTID(alpha=0.05, n=40, CV=0.50, theta0=0.95, design=\"2x2x4\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-085",
      "template": "bioequivalence_dual",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a dual bioequivalence criterion study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is c(0.20. The expected geometric mean ratio (test/reference) is c(0.95. With 80% power at significance level of c(0.05, how many subjects are required?",
      "expected_template": "bioequivalence_dual",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.8226
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0247
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.2TOST",
        "origin": "PowerTOST::sampleN.2TOST CRAN docs / direct computation",
        "variation": "2tost_cv20_25_rho75"
      },
      "reference_code": "library(PowerTOST)\nsampleN.2TOST(alpha=c(0.05,0.05), targetpower=0.80, CV=c(0.20,0.25), theta0=c(0.95,0.95), rho=0.75, design=\"2x2\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-086",
      "template": "bioequivalence_dual",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a dual bioequivalence criterion study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is c(0.20. The expected geometric mean ratio (test/reference) is c(0.95. With 80% power at significance level of c(0.05, how many subjects are required?",
      "expected_template": "bioequivalence_dual",
      "ground_truth": {
        "sample_size": 40,
        "power": 0.8095
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0243
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.2TOST",
        "origin": "PowerTOST::sampleN.2TOST CRAN docs / direct computation",
        "variation": "2tost_cv20_30_rho50"
      },
      "reference_code": "library(PowerTOST)\nsampleN.2TOST(alpha=c(0.05,0.05), targetpower=0.80, CV=c(0.20,0.30), theta0=c(0.95,0.95), rho=0.50, design=\"2x2\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-087",
      "template": "bioequivalence_dual",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a dual bioequivalence criterion study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is c(0.25. The expected geometric mean ratio (test/reference) is c(0.95. With 80% power at significance level of c(0.05, how many subjects are required?",
      "expected_template": "bioequivalence_dual",
      "ground_truth": {
        "sample_size": 40,
        "power": 0.8002
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.2TOST",
        "origin": "PowerTOST::sampleN.2TOST CRAN docs / direct computation",
        "variation": "2tost_cv25_30_rho80"
      },
      "reference_code": "library(PowerTOST)\nsampleN.2TOST(alpha=c(0.05,0.05), targetpower=0.80, CV=c(0.25,0.30), theta0=c(0.95,0.95), rho=0.80, design=\"2x2\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-088",
      "template": "bioequivalence_dual",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a dual bioequivalence criterion study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is c(0.20. The expected geometric mean ratio (test/reference) is c(0.95. With 80% power at significance level of c(0.05, how many subjects are required?",
      "expected_template": "bioequivalence_dual",
      "ground_truth": {
        "sample_size": 22,
        "power": 0.8294
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0249
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.2TOST",
        "origin": "PowerTOST::sampleN.2TOST CRAN docs / direct computation",
        "variation": "2tost_cv20_20_rho90"
      },
      "reference_code": "library(PowerTOST)\nsampleN.2TOST(alpha=c(0.05,0.05), targetpower=0.80, CV=c(0.20,0.20), theta0=c(0.95,0.95), rho=0.90, design=\"2x2\", print=FALSE, nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-089",
      "template": "bioequivalence_dual",
      "difficulty": "advanced",
      "question": "A dual bioequivalence criterion study uses a 2x2 crossover design with 30 participants per group. The within-subject coefficient of variation (CV) is c(0.20. The expected geometric mean ratio (test/reference) is c(0.95. What power is achieved at significance level of c(0.05?",
      "expected_template": "bioequivalence_dual",
      "ground_truth": {
        "power": 0.8226
      },
      "tolerance": {
        "power": 0.0247
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.2TOST",
        "origin": "PowerTOST::power.2TOST CRAN docs / direct computation",
        "variation": "p2tost_n30_cv20_25"
      },
      "reference_code": "library(PowerTOST)\npower.2TOST(alpha=c(0.05,0.05), n=30, CV=c(0.20,0.25), theta0=c(0.95,0.95), rho=0.75, design=\"2x2\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-090",
      "template": "bioequivalence_dual",
      "difficulty": "advanced",
      "question": "A dual bioequivalence criterion study uses a 2x2 crossover design with 36 participants per group. The within-subject coefficient of variation (CV) is c(0.25. The expected geometric mean ratio (test/reference) is c(0.95. What power is achieved at significance level of c(0.05?",
      "expected_template": "bioequivalence_dual",
      "ground_truth": {
        "power": 0.7524
      },
      "tolerance": {
        "power": 0.0226
      },
      "source": {
        "package": "PowerTOST",
        "function": "power.2TOST",
        "origin": "PowerTOST::power.2TOST CRAN docs / direct computation",
        "variation": "p2tost_n36_cv25_30"
      },
      "reference_code": "library(PowerTOST)\npower.2TOST(alpha=c(0.05,0.05), n=36, CV=c(0.25,0.30), theta0=c(0.95,0.95), rho=0.80, design=\"2x2\", nsims=1e5)",
      "tier": 3
    },
    {
      "id": "t3-ptost-091",
      "template": "bioequivalence_ratiof",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a bioequivalence using ratio of formulations study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.025, how many subjects are required?",
      "expected_template": "bioequivalence_ratiof",
      "ground_truth": {
        "sample_size": 28,
        "power": 0.8078
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0242
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RatioF",
        "origin": "PowerTOST::sampleN.RatioF CRAN docs / direct computation",
        "variation": "ratiof_22_cv20_cvb40"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RatioF(alpha=0.025, targetpower=0.80, CV=0.20, CVb=0.40, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-092",
      "template": "bioequivalence_ratiof",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a bioequivalence using ratio of formulations study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.025, how many subjects are required?",
      "expected_template": "bioequivalence_ratiof",
      "ground_truth": {
        "sample_size": 42,
        "power": 0.8022
      },
      "tolerance": {
        "sample_size": 3,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RatioF",
        "origin": "PowerTOST::sampleN.RatioF CRAN docs / direct computation",
        "variation": "ratiof_22_cv25_cvb50"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RatioF(alpha=0.025, targetpower=0.80, CV=0.25, CVb=0.50, theta0=0.95, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-093",
      "template": "bioequivalence_ratiof",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a bioequivalence using ratio of formulations study using a 2x2 crossover design. The within-subject coefficient of variation (CV) is 0.3. The expected geometric mean ratio (test/reference) is 0.9. With 80% power at significance level of 0.025, how many subjects are required?",
      "expected_template": "bioequivalence_ratiof",
      "ground_truth": {
        "sample_size": 126,
        "power": 0.8011
      },
      "tolerance": {
        "sample_size": 7,
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RatioF",
        "origin": "PowerTOST::sampleN.RatioF CRAN docs / direct computation",
        "variation": "ratiof_22_cv30_cvb50"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RatioF(alpha=0.025, targetpower=0.80, CV=0.30, CVb=0.50, theta0=0.90, design=\"2x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-094",
      "template": "bioequivalence_ratiof",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a bioequivalence using ratio of formulations study using a parallel crossover design. The within-subject coefficient of variation (CV) is 0.4. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.025, how many subjects are required?",
      "expected_template": "bioequivalence_ratiof",
      "ground_truth": {
        "sample_size": 188,
        "power": 0.8011
      },
      "tolerance": {
        "sample_size": 10,
        "power": 0.024
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.RatioF",
        "origin": "PowerTOST::sampleN.RatioF CRAN docs / direct computation",
        "variation": "ratiof_parallel_cv40"
      },
      "reference_code": "library(PowerTOST)\nsampleN.RatioF(alpha=0.025, targetpower=0.80, CV=0.40, theta0=0.95, design=\"parallel\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-095",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 3x3 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 27,
        "power": 0.8035
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0241
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_3x3_cv25"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=0.95, design=\"3x3\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-096",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 4x4 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 28,
        "power": 0.821
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0246
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_4x4_cv25"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=0.95, design=\"4x4\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-097",
      "template": "bioequivalence_tost",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x4x2 crossover design. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 108,
        "power": 0.8091
      },
      "tolerance": {
        "sample_size": 6,
        "power": 0.0243
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_2x4x2_cv25"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.25, theta0=0.95, design=\"2x4x2\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-098",
      "template": "bioequivalence_tost",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a paired crossover design. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_tost",
      "ground_truth": {
        "sample_size": 19,
        "power": 0.8161
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.0245
      },
      "source": {
        "package": "PowerTOST",
        "function": "sampleN.TOST",
        "origin": "PowerTOST::sampleN.TOST CRAN docs / direct computation",
        "variation": "tost_paired_cv20"
      },
      "reference_code": "library(PowerTOST)\nsampleN.TOST(alpha=0.05, targetpower=0.80, CV=0.20, theta0=0.95, design=\"paired\", print=FALSE)",
      "tier": 3
    },
    {
      "id": "t3-ptost-099",
      "template": "bioequivalence_expected",
      "difficulty": "advanced",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 24 participants per group. The within-subject coefficient of variation (CV) is 0.2. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_expected",
      "ground_truth": {
        "power": 0.8638
      },
      "tolerance": {
        "power": 0.0259
      },
      "source": {
        "package": "PowerTOST",
        "function": "exppower.TOST",
        "origin": "PowerTOST::exppower.TOST CRAN docs / direct computation",
        "variation": "exppower_n24_cv20"
      },
      "reference_code": "library(PowerTOST)\nexppower.TOST(alpha=0.05, n=24, CV=0.20, theta0=0.95, design=\"2x2\", prior.parm=list(m=24, design=\"2x2\"), prior.type=\"CV\")",
      "tier": 3
    },
    {
      "id": "t3-ptost-100",
      "template": "bioequivalence_expected",
      "difficulty": "advanced",
      "question": "A average bioequivalence (TOST) study uses a 2x2 crossover design with 36 participants per group. The within-subject coefficient of variation (CV) is 0.25. The expected geometric mean ratio (test/reference) is 0.95. What power is achieved at significance level of 0.05?",
      "expected_template": "bioequivalence_expected",
      "ground_truth": {
        "power": 0.8618
      },
      "tolerance": {
        "power": 0.0259
      },
      "source": {
        "package": "PowerTOST",
        "function": "exppower.TOST",
        "origin": "PowerTOST::exppower.TOST CRAN docs / direct computation",
        "variation": "exppower_n36_cv25"
      },
      "reference_code": "library(PowerTOST)\nexppower.TOST(alpha=0.05, n=36, CV=0.25, theta0=0.95, design=\"2x2\", prior.parm=list(m=24, design=\"2x2\"), prior.type=\"CV\")",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-001",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A pulmonologist is planning a group sequential adaptive trial with 1 stages for psoriasis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 128,
        "max_sample_size_calc": 128,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_fixed_d05_sd1"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-002",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A rheumatologist is planning a group sequential adaptive trial with 1 stages for epilepsy. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 128,
        "max_sample_size_calc": 128,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_fixed_d1_sd2"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getSampleSizeMeans(d, alternative=1.0, stDev=2.0) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-003",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A dermatologist is planning a group sequential adaptive trial with 1 stages for hypertension. At significance level of 0.05 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 128,
        "max_sample_size_calc": 128,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_fixed_2sided_d05"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.05, sided=2, beta=0.2); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-004",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A ophthalmologist is planning a group sequential adaptive trial with 1 stages for type 2 diabetes. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 469,
        "max_sample_size_calc": 469,
        "n_fixed": 469
      },
      "tolerance": {
        "max_sample_size": 24,
        "max_sample_size_calc": 24,
        "n_fixed": 24
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_fixed_d03_p90"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.1); getSampleSizeMeans(d, alternative=0.3, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-005",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A nephrologist is planning a group sequential adaptive trial with 2 stages for major depressive disorder. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 129,
        "max_sample_size_calc": 129,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_2look_OF_d05"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-006",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A infectious disease specialist is planning a group sequential adaptive trial with 2 stages for chronic pain. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 142,
        "max_sample_size_calc": 142,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 8,
        "max_sample_size_calc": 8,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_2look_Pocock_d05"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"P\"); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-007",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A psychologist is planning a group sequential adaptive trial with 2 stages for asthma. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 172,
        "max_sample_size_calc": 172,
        "n_fixed": 171
      },
      "tolerance": {
        "max_sample_size": 9,
        "max_sample_size_calc": 9,
        "n_fixed": 9
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_2look_OF_d1_sd2_p90"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.1, typeOfDesign=\"OF\"); getSampleSizeMeans(d, alternative=1.0, stDev=2.0) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-008",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A educational researcher is planning a group sequential adaptive trial with 2 stages for COPD. At significance level of 0.05 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 129,
        "max_sample_size_calc": 129,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_2look_OF_2sided"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.05, sided=2, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-009",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A epidemiologist is planning a group sequential adaptive trial with 3 stages for rheumatoid arthritis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 357,
        "max_sample_size_calc": 357,
        "n_fixed": 351
      },
      "tolerance": {
        "max_sample_size": 18,
        "max_sample_size_calc": 18,
        "n_fixed": 18
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_3look_OF_d03"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeMeans(d, alternative=0.3, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-010",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A nurse researcher is planning a group sequential adaptive trial with 3 stages for breast cancer. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 332,
        "max_sample_size_calc": 332,
        "n_fixed": 285
      },
      "tolerance": {
        "max_sample_size": 17,
        "max_sample_size_calc": 17,
        "n_fixed": 15
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_3look_P_d05_sd15"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"P\"); getSampleSizeMeans(d, alternative=0.5, stDev=1.5) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-011",
      "template": "adaptive_trial",
      "difficulty": "advanced",
      "question": "A social scientist is planning a group sequential adaptive trial with 3 stages for heart failure. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 130,
        "max_sample_size_calc": 130,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_3look_HSD_d05"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"asHSD\", gammaA=-4); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-012",
      "template": "adaptive_trial",
      "difficulty": "advanced",
      "question": "A pharmacist researcher is planning a group sequential adaptive trial with 4 stages for Alzheimer's disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 131,
        "max_sample_size_calc": 131,
        "n_fixed": 128
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_4look_OF_d05"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=4, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizemeans-013",
      "template": "adaptive_trial",
      "difficulty": "advanced",
      "question": "A gerontologist is planning a group sequential adaptive trial with 3 stages for Parkinson's disease. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 182,
        "max_sample_size_calc": 182,
        "n_fixed": 171
      },
      "tolerance": {
        "max_sample_size": 10,
        "max_sample_size_calc": 10,
        "n_fixed": 9
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeMeans",
        "origin": "rpact::getSampleSizeMeans CRAN documentation",
        "variation": "means_3look_HSD_betaspend_p90"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.1, typeOfDesign=\"asHSD\", gammaA=-4, typeBetaSpending=\"bsHSD\", gammaB=-2); getSampleSizeMeans(d, alternative=0.5, stDev=1) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizerates-014",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A sports medicine physician is planning a group sequential adaptive trial with 1 stages for multiple sclerosis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 163,
        "max_sample_size_calc": 163,
        "n_fixed": 163
      },
      "tolerance": {
        "max_sample_size": 9,
        "max_sample_size_calc": 9,
        "n_fixed": 9
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeRates",
        "origin": "rpact::getSampleSizeRates CRAN documentation",
        "variation": "rates_fixed_40v20"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getSampleSizeRates(d, pi1=0.40, pi2=0.20) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizerates-015",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A allergist is planning a group sequential adaptive trial with 1 stages for chronic kidney disease. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 241,
        "max_sample_size_calc": 241,
        "n_fixed": 241
      },
      "tolerance": {
        "max_sample_size": 13,
        "max_sample_size_calc": 13,
        "n_fixed": 13
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeRates",
        "origin": "rpact::getSampleSizeRates CRAN documentation",
        "variation": "rates_fixed_30v15"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getSampleSizeRates(d, pi1=0.30, pi2=0.15) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizerates-016",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A urologist is planning a group sequential adaptive trial with 1 stages for inflammatory bowel disease. At significance level of 0.05 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 186,
        "max_sample_size_calc": 186,
        "n_fixed": 186
      },
      "tolerance": {
        "max_sample_size": 10,
        "max_sample_size_calc": 10,
        "n_fixed": 10
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeRates",
        "origin": "rpact::getSampleSizeRates CRAN documentation",
        "variation": "rates_fixed_50v30_2sided"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.05, sided=2, beta=0.2); getSampleSizeRates(d, pi1=0.50, pi2=0.30) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizerates-017",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A hematologist is planning a group sequential adaptive trial with 2 stages for migraine. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 243,
        "max_sample_size_calc": 243,
        "n_fixed": 241
      },
      "tolerance": {
        "max_sample_size": 13,
        "max_sample_size_calc": 13,
        "n_fixed": 13
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeRates",
        "origin": "rpact::getSampleSizeRates CRAN documentation",
        "variation": "rates_2look_OF_30v15"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeRates(d, pi1=0.30, pi2=0.15) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizerates-018",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A clinical nutritionist is planning a group sequential adaptive trial with 3 stages for generalized anxiety disorder. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 166,
        "max_sample_size_calc": 166,
        "n_fixed": 163
      },
      "tolerance": {
        "max_sample_size": 9,
        "max_sample_size_calc": 9,
        "n_fixed": 9
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeRates",
        "origin": "rpact::getSampleSizeRates CRAN documentation",
        "variation": "rates_3look_OF_40v20"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeRates(d, pi1=0.40, pi2=0.20) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizerates-019",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A rehabilitation specialist is planning a group sequential adaptive trial with 2 stages for osteoarthritis. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 293,
        "max_sample_size_calc": 293,
        "n_fixed": 266
      },
      "tolerance": {
        "max_sample_size": 15,
        "max_sample_size_calc": 15,
        "n_fixed": 14
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeRates",
        "origin": "rpact::getSampleSizeRates CRAN documentation",
        "variation": "rates_2look_P_25v10_p90"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.1, typeOfDesign=\"P\"); getSampleSizeRates(d, pi1=0.25, pi2=0.10) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizerates-020",
      "template": "adaptive_trial",
      "difficulty": "advanced",
      "question": "A occupational therapist is planning a group sequential adaptive trial with 3 stages for atrial fibrillation. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 281,
        "max_sample_size_calc": 281,
        "n_fixed": 276
      },
      "tolerance": {
        "max_sample_size": 15,
        "max_sample_size_calc": 15,
        "n_fixed": 14
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeRates",
        "origin": "rpact::getSampleSizeRates CRAN documentation",
        "variation": "rates_3look_HSD_35v20"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"asHSD\", gammaA=-4); getSampleSizeRates(d, pi1=0.35, pi2=0.20) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizesurvival-021",
      "template": "adaptive_trial_survival",
      "difficulty": "intermediate",
      "question": "A speech pathologist is planning a group sequential adaptive trial with 1 stages for a time-to-event endpoint for psoriasis. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial_survival",
      "ground_truth": {
        "max_sample_size": 540,
        "max_sample_size_calc": 540,
        "max_events": 380,
        "n_fixed": 540,
        "events_fixed": 380
      },
      "tolerance": {
        "max_sample_size": 27,
        "max_sample_size_calc": 27,
        "max_events": 19,
        "n_fixed": 27,
        "events_fixed": 19
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeSurvival",
        "origin": "rpact::getSampleSizeSurvival CRAN documentation",
        "variation": "surv_fixed_hr075"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getSampleSizeSurvival(d, lambda2=log(2)/12, hazardRatio=0.75, accrualTime=c(0,18), accrualIntensity=30, followUpTime=12) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizesurvival-022",
      "template": "adaptive_trial_survival",
      "difficulty": "intermediate",
      "question": "A physical therapist is planning a group sequential adaptive trial with 1 stages for a time-to-event endpoint for epilepsy. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial_survival",
      "ground_truth": {
        "max_sample_size": 360,
        "max_sample_size_calc": 360,
        "max_events": 247,
        "n_fixed": 360,
        "events_fixed": 247
      },
      "tolerance": {
        "max_sample_size": 18,
        "max_sample_size_calc": 18,
        "max_events": 13,
        "n_fixed": 18,
        "events_fixed": 13
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeSurvival",
        "origin": "rpact::getSampleSizeSurvival CRAN documentation",
        "variation": "surv_fixed_hr070_med24"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getSampleSizeSurvival(d, lambda2=log(2)/24, hazardRatio=0.70, accrualTime=c(0,24), accrualIntensity=15, followUpTime=18) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizesurvival-023",
      "template": "adaptive_trial_survival",
      "difficulty": "intermediate",
      "question": "A cardiologist is planning a group sequential adaptive trial with 1 stages for a time-to-event endpoint for hypertension. At significance level of 0.025 with 90% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial_survival",
      "ground_truth": {
        "max_sample_size": 540,
        "max_sample_size_calc": 540,
        "max_events": 508,
        "n_fixed": 540,
        "events_fixed": 508
      },
      "tolerance": {
        "max_sample_size": 27,
        "max_sample_size_calc": 27,
        "max_events": 26,
        "n_fixed": 27,
        "events_fixed": 26
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeSurvival",
        "origin": "rpact::getSampleSizeSurvival CRAN documentation",
        "variation": "surv_fixed_hr075_p90"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.1); getSampleSizeSurvival(d, lambda2=log(2)/12, hazardRatio=0.75, accrualTime=c(0,18), accrualIntensity=30, followUpTime=12) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizesurvival-024",
      "template": "adaptive_trial_survival",
      "difficulty": "advanced",
      "question": "A oncologist is planning a group sequential adaptive trial with 2 stages for a time-to-event endpoint for type 2 diabetes. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial_survival",
      "ground_truth": {
        "max_sample_size": 540,
        "max_sample_size_calc": 540,
        "max_events": 383,
        "n_fixed": 540,
        "events_fixed": 380
      },
      "tolerance": {
        "max_sample_size": 27,
        "max_sample_size_calc": 27,
        "max_events": 20,
        "n_fixed": 27,
        "events_fixed": 19
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeSurvival",
        "origin": "rpact::getSampleSizeSurvival CRAN documentation",
        "variation": "surv_2look_OF_hr075"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeSurvival(d, lambda2=log(2)/12, hazardRatio=0.75, accrualTime=c(0,18), accrualIntensity=30, followUpTime=12) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getsamplesizesurvival-025",
      "template": "adaptive_trial_survival",
      "difficulty": "advanced",
      "question": "A neurologist is planning a group sequential adaptive trial with 3 stages for a time-to-event endpoint for major depressive disorder. At significance level of 0.025 with 80% power, what maximum sample size is required?",
      "expected_template": "adaptive_trial_survival",
      "ground_truth": {
        "max_sample_size": 480,
        "max_sample_size_calc": 480,
        "max_events": 252,
        "n_fixed": 480,
        "events_fixed": 247
      },
      "tolerance": {
        "max_sample_size": 24,
        "max_sample_size_calc": 24,
        "max_events": 13,
        "n_fixed": 24,
        "events_fixed": 13
      },
      "source": {
        "package": "rpact",
        "function": "getSampleSizeSurvival",
        "origin": "rpact::getSampleSizeSurvival CRAN documentation",
        "variation": "surv_3look_OF_hr070_med18"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getSampleSizeSurvival(d, lambda2=log(2)/18, hazardRatio=0.70, accrualTime=c(0,24), accrualIntensity=20, followUpTime=18) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getpowermeans-026",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A psychiatrist has 130 participants for a group sequential adaptive trial with 1 stages studying chronic pain. What power is achieved at significance level of 0.025?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 130,
        "max_sample_size_calc": 130,
        "n_fixed": 130
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7,
        "n_fixed": 7
      },
      "source": {
        "package": "rpact",
        "function": "getPowerMeans",
        "origin": "rpact::getPowerMeans CRAN documentation",
        "variation": "power_means_n130"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getPowerMeans(d, alternative=0.5, stDev=1, maxNumberOfSubjects=130) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getpowermeans-027",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A pediatrician has 130 participants for a group sequential adaptive trial with 2 stages studying asthma. What power is achieved at significance level of 0.025?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 130,
        "max_sample_size_calc": 130
      },
      "tolerance": {
        "max_sample_size": 7,
        "max_sample_size_calc": 7
      },
      "source": {
        "package": "rpact",
        "function": "getPowerMeans",
        "origin": "rpact::getPowerMeans CRAN documentation",
        "variation": "power_means_2look_OF_n130"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getPowerMeans(d, alternative=0.5, stDev=1, maxNumberOfSubjects=130) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getpowermeans-028",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A endocrinologist has 300 participants for a group sequential adaptive trial with 3 stages studying COPD. What power is achieved at significance level of 0.025?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 300,
        "max_sample_size_calc": 300
      },
      "tolerance": {
        "max_sample_size": 15,
        "max_sample_size_calc": 15
      },
      "source": {
        "package": "rpact",
        "function": "getPowerMeans",
        "origin": "rpact::getPowerMeans CRAN documentation",
        "variation": "power_means_3look_OF_d03_n300"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=3, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getPowerMeans(d, alternative=0.3, stDev=1, maxNumberOfSubjects=300) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getpowerrates-029",
      "template": "adaptive_trial",
      "difficulty": "basic",
      "question": "A orthopedic surgeon has 160 participants for a group sequential adaptive trial with 1 stages studying rheumatoid arthritis. What power is achieved at significance level of 0.025?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 160,
        "max_sample_size_calc": 160,
        "n_fixed": 160
      },
      "tolerance": {
        "max_sample_size": 8,
        "max_sample_size_calc": 8,
        "n_fixed": 8
      },
      "source": {
        "package": "rpact",
        "function": "getPowerRates",
        "origin": "rpact::getPowerRates CRAN documentation",
        "variation": "power_rates_n160"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=1, alpha=0.025, sided=1, beta=0.2); getPowerRates(d, pi1=0.40, pi2=0.20, maxNumberOfSubjects=160) }",
      "tier": 3
    },
    {
      "id": "t3-rpact-getpowerrates-030",
      "template": "adaptive_trial",
      "difficulty": "intermediate",
      "question": "A gastroenterologist has 250 participants for a group sequential adaptive trial with 2 stages studying breast cancer. What power is achieved at significance level of 0.025?",
      "expected_template": "adaptive_trial",
      "ground_truth": {
        "max_sample_size": 250,
        "max_sample_size_calc": 250
      },
      "tolerance": {
        "max_sample_size": 13,
        "max_sample_size_calc": 13
      },
      "source": {
        "package": "rpact",
        "function": "getPowerRates",
        "origin": "rpact::getPowerRates CRAN documentation",
        "variation": "power_rates_2look_OF_n250"
      },
      "reference_code": "library(rpact)\n{ d <- getDesignGroupSequential(kMax=2, alpha=0.025, sided=1, beta=0.2, typeOfDesign=\"OF\"); getPowerRates(d, pi1=0.30, pi2=0.15, maxNumberOfSubjects=250) }",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-011",
      "template": "non_inferiority_mean",
      "difficulty": "intermediate",
      "question": "A social scientist is designing a non-inferiority trial for psoriasis using a continuous endpoint. The non-inferiority margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_mean",
      "ground_truth": {
        "sample_size": 50
      },
      "tolerance": {
        "sample_size": 3
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_nis_delta0_margin5"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.05, beta=0.20, sigma=10, k=1, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-012",
      "template": "non_inferiority_mean",
      "difficulty": "intermediate",
      "question": "A pharmacist researcher is designing a non-inferiority trial for epilepsy using a continuous endpoint. The non-inferiority margin is 3. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_mean",
      "ground_truth": {
        "sample_size": 138
      },
      "tolerance": {
        "sample_size": 7
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_nis_delta0_margin3"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.05, beta=0.20, sigma=10, k=1, delta=0, margin=3)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-013",
      "template": "non_inferiority_mean",
      "difficulty": "intermediate",
      "question": "A gerontologist is designing a non-inferiority trial for hypertension using a continuous endpoint. The non-inferiority margin is 5. At significance level of 0.05 with 90% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_mean",
      "ground_truth": {
        "sample_size": 69
      },
      "tolerance": {
        "sample_size": 4
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_nis_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.05, beta=0.10, sigma=10, k=1, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-014",
      "template": "non_inferiority_mean",
      "difficulty": "advanced",
      "question": "A sports medicine physician is designing a non-inferiority trial for type 2 diabetes using a continuous endpoint. The non-inferiority margin is 5. At significance level of 0.025 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_mean",
      "ground_truth": {
        "sample_size": 63
      },
      "tolerance": {
        "sample_size": 4
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_nis_a025"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.025, beta=0.20, sigma=10, k=1, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-015",
      "template": "non_inferiority_mean",
      "difficulty": "intermediate",
      "question": "A allergist is designing a non-inferiority trial for major depressive disorder using a continuous endpoint. The non-inferiority margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_mean",
      "ground_truth": {
        "sample_size": 112
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_nis_sd15"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.05, beta=0.20, sigma=15, k=1, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-016",
      "template": "superiority_mean",
      "difficulty": "advanced",
      "question": "A urologist is designing a superiority trial for chronic pain using a continuous endpoint. The superiority margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "superiority_mean",
      "ground_truth": {
        "sample_size": 138
      },
      "tolerance": {
        "sample_size": 7
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_nis_delta2_margin5"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.05, beta=0.20, sigma=10, k=1, delta=2, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeanequivalence-017",
      "template": "equivalence_mean",
      "difficulty": "advanced",
      "question": "A hematologist is designing a equivalence trial for asthma using a continuous endpoint. The equivalence margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_mean",
      "ground_truth": {
        "sample_size": 69
      },
      "tolerance": {
        "sample_size": 4
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.Equivalence",
        "origin": "TrialSize::TwoSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mean_equiv_delta0_margin5"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.Equivalence(alpha=0.05, beta=0.20, sigma=10, k=1, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeanequivalence-018",
      "template": "equivalence_mean",
      "difficulty": "advanced",
      "question": "A clinical nutritionist is designing a equivalence trial for COPD using a continuous endpoint. The equivalence margin is 3. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_mean",
      "ground_truth": {
        "sample_size": 191
      },
      "tolerance": {
        "sample_size": 10
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.Equivalence",
        "origin": "TrialSize::TwoSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mean_equiv_delta0_margin3"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.Equivalence(alpha=0.05, beta=0.20, sigma=10, k=1, delta=0, margin=3)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeanequivalence-019",
      "template": "equivalence_mean",
      "difficulty": "advanced",
      "question": "A rehabilitation specialist is designing a equivalence trial for rheumatoid arthritis using a continuous endpoint. The equivalence margin is 5. At significance level of 0.05 with 90% power, how many subjects per group are needed?",
      "expected_template": "equivalence_mean",
      "ground_truth": {
        "sample_size": 87
      },
      "tolerance": {
        "sample_size": 5
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.Equivalence",
        "origin": "TrialSize::TwoSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mean_equiv_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.Equivalence(alpha=0.05, beta=0.10, sigma=10, k=1, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeanequivalence-020",
      "template": "equivalence_mean",
      "difficulty": "advanced",
      "question": "A occupational therapist is designing a equivalence trial for breast cancer using a continuous endpoint. The equivalence margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_mean",
      "ground_truth": {
        "sample_size": 155
      },
      "tolerance": {
        "sample_size": 8
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.Equivalence",
        "origin": "TrialSize::TwoSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mean_equiv_sd15"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.Equivalence(alpha=0.05, beta=0.20, sigma=15, k=1, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeanequivalence-021",
      "template": "equivalence_mean",
      "difficulty": "advanced",
      "question": "A speech pathologist is designing a equivalence trial for heart failure using a continuous endpoint. The equivalence margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_mean",
      "ground_truth": {
        "sample_size": 103
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.Equivalence",
        "origin": "TrialSize::TwoSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mean_equiv_k2"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.Equivalence(alpha=0.05, beta=0.20, sigma=10, k=2, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesamplemeannis-028",
      "template": "non_inferiority_1mean",
      "difficulty": "intermediate",
      "question": "A endocrinologist is designing a non-inferiority trial for generalized anxiety disorder using a continuous endpoint. with specified margin. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_1mean",
      "ground_truth": {
        "sample_size": 25
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleMean.NIS",
        "origin": "TrialSize::OneSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "1mean_nis_delta5"
      },
      "reference_code": "library(TrialSize)\nOneSampleMean.NIS(alpha=0.05, beta=0.20, sigma=10, margin=0, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesamplemeannis-029",
      "template": "non_inferiority_1mean",
      "difficulty": "intermediate",
      "question": "A orthopedic surgeon is designing a non-inferiority trial for osteoarthritis using a continuous endpoint. with specified margin. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_1mean",
      "ground_truth": {
        "sample_size": 69
      },
      "tolerance": {
        "sample_size": 4
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleMean.NIS",
        "origin": "TrialSize::OneSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "1mean_nis_delta3"
      },
      "reference_code": "library(TrialSize)\nOneSampleMean.NIS(alpha=0.05, beta=0.20, sigma=10, margin=0, delta=3)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesamplemeannis-030",
      "template": "non_inferiority_1mean",
      "difficulty": "intermediate",
      "question": "A gastroenterologist is designing a non-inferiority trial for atrial fibrillation using a continuous endpoint. with specified margin. At significance level of 0.05 with 90% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_1mean",
      "ground_truth": {
        "sample_size": 35
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleMean.NIS",
        "origin": "TrialSize::OneSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "1mean_nis_p90"
      },
      "reference_code": "library(TrialSize)\nOneSampleMean.NIS(alpha=0.05, beta=0.10, sigma=10, margin=0, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesamplemeanequivalence-031",
      "template": "equivalence_1mean",
      "difficulty": "advanced",
      "question": "A pulmonologist is designing a equivalence trial for psoriasis using a continuous endpoint. with specified margins. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_1mean",
      "ground_truth": {
        "sample_size": 35
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleMean.Equivalence",
        "origin": "TrialSize::OneSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "1mean_equiv_delta5"
      },
      "reference_code": "library(TrialSize)\nOneSampleMean.Equivalence(alpha=0.05, beta=0.20, sigma=10, margin=0, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesamplemeanequivalence-032",
      "template": "equivalence_1mean",
      "difficulty": "advanced",
      "question": "A rheumatologist is designing a equivalence trial for epilepsy using a continuous endpoint. with specified margins. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_1mean",
      "ground_truth": {
        "sample_size": 96
      },
      "tolerance": {
        "sample_size": 5
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleMean.Equivalence",
        "origin": "TrialSize::OneSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "1mean_equiv_delta3"
      },
      "reference_code": "library(TrialSize)\nOneSampleMean.Equivalence(alpha=0.05, beta=0.20, sigma=10, margin=0, delta=3)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesamplemeanequivalence-033",
      "template": "equivalence_1mean",
      "difficulty": "advanced",
      "question": "A dermatologist is designing a equivalence trial for hypertension using a continuous endpoint. with specified margins. At significance level of 0.05 with 90% power, how many subjects per group are needed?",
      "expected_template": "equivalence_1mean",
      "ground_truth": {
        "sample_size": 44
      },
      "tolerance": {
        "sample_size": 3
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleMean.Equivalence",
        "origin": "TrialSize::OneSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "1mean_equiv_p90"
      },
      "reference_code": "library(TrialSize)\nOneSampleMean.Equivalence(alpha=0.05, beta=0.10, sigma=10, margin=0, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionnis-044",
      "template": "non_inferiority_prop",
      "difficulty": "intermediate",
      "question": "A sports medicine physician is designing a non-inferiority trial for multiple sclerosis using a proportion endpoint. The non-inferiority margin is 0.15. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_prop",
      "ground_truth": {
        "sample_size": 116
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.NIS",
        "origin": "TrialSize::TwoSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "prop_nis_30_margin15"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.NIS(alpha=0.05, beta=0.20, p1=0.30, p2=0.30, k=1, delta=0, margin=0.15)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionnis-045",
      "template": "non_inferiority_prop",
      "difficulty": "intermediate",
      "question": "A allergist is designing a non-inferiority trial for chronic kidney disease using a proportion endpoint. The non-inferiority margin is 0.1. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_prop",
      "ground_truth": {
        "sample_size": 310
      },
      "tolerance": {
        "sample_size": 16
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.NIS",
        "origin": "TrialSize::TwoSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "prop_nis_50_margin10"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.NIS(alpha=0.05, beta=0.20, p1=0.50, p2=0.50, k=1, delta=0, margin=0.10)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionnis-046",
      "template": "non_inferiority_prop",
      "difficulty": "advanced",
      "question": "A urologist is designing a non-inferiority trial for inflammatory bowel disease using a proportion endpoint. The non-inferiority margin is 0.15. At significance level of 0.05 with 90% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_prop",
      "ground_truth": {
        "sample_size": 160
      },
      "tolerance": {
        "sample_size": 8
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.NIS",
        "origin": "TrialSize::TwoSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "prop_nis_30_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.NIS(alpha=0.05, beta=0.10, p1=0.30, p2=0.30, k=1, delta=0, margin=0.15)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionnis-047",
      "template": "non_inferiority_prop",
      "difficulty": "advanced",
      "question": "A hematologist is designing a non-inferiority trial for migraine using a proportion endpoint. The non-inferiority margin is 0.1. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_prop",
      "ground_truth": {
        "sample_size": 198
      },
      "tolerance": {
        "sample_size": 10
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.NIS",
        "origin": "TrialSize::TwoSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "prop_nis_20_margin10"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.NIS(alpha=0.05, beta=0.20, p1=0.20, p2=0.20, k=1, delta=0, margin=0.10)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionequivalence-048",
      "template": "equivalence_prop",
      "difficulty": "advanced",
      "question": "A clinical nutritionist is designing a equivalence trial for generalized anxiety disorder using a proportion endpoint. The equivalence margin is 0.15. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_prop",
      "ground_truth": {
        "sample_size": 160
      },
      "tolerance": {
        "sample_size": 8
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.Equivalence",
        "origin": "TrialSize::TwoSampleProportion.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "prop_equiv_30_margin15"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.Equivalence(alpha=0.05, beta=0.20, p1=0.30, p2=0.30, k=1, delta=0, margin=0.15)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionequivalence-049",
      "template": "equivalence_prop",
      "difficulty": "advanced",
      "question": "A rehabilitation specialist is designing a equivalence trial for osteoarthritis using a proportion endpoint. The equivalence margin is 0.1. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_prop",
      "ground_truth": {
        "sample_size": 429
      },
      "tolerance": {
        "sample_size": 22
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.Equivalence",
        "origin": "TrialSize::TwoSampleProportion.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "prop_equiv_50_margin10"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.Equivalence(alpha=0.05, beta=0.20, p1=0.50, p2=0.50, k=1, delta=0, margin=0.10)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionequivalence-050",
      "template": "equivalence_prop",
      "difficulty": "advanced",
      "question": "A occupational therapist is designing a equivalence trial for atrial fibrillation using a proportion endpoint. The equivalence margin is 0.15. At significance level of 0.05 with 90% power, how many subjects per group are needed?",
      "expected_template": "equivalence_prop",
      "ground_truth": {
        "sample_size": 203
      },
      "tolerance": {
        "sample_size": 11
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.Equivalence",
        "origin": "TrialSize::TwoSampleProportion.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "prop_equiv_30_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.Equivalence(alpha=0.05, beta=0.10, p1=0.30, p2=0.30, k=1, delta=0, margin=0.15)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesampleproportionnis-057",
      "template": "non_inferiority_1prop",
      "difficulty": "intermediate",
      "question": "A pediatrician is designing a non-inferiority trial for asthma using a proportion endpoint. The non-inferiority margin is 0.1. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_1prop",
      "ground_truth": {
        "sample_size": 520
      },
      "tolerance": {
        "sample_size": 26
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleProportion.NIS",
        "origin": "TrialSize::OneSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "1prop_nis_30_delta10"
      },
      "reference_code": "library(TrialSize)\nOneSampleProportion.NIS(alpha=0.05, beta=0.20, p=0.30, delta=0.10, differ=0.05)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesampleproportionnis-058",
      "template": "non_inferiority_1prop",
      "difficulty": "intermediate",
      "question": "A endocrinologist is designing a non-inferiority trial for COPD using a proportion endpoint. The non-inferiority margin is 0.1. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_1prop",
      "ground_truth": {
        "sample_size": 619
      },
      "tolerance": {
        "sample_size": 31
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleProportion.NIS",
        "origin": "TrialSize::OneSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "1prop_nis_50_delta10"
      },
      "reference_code": "library(TrialSize)\nOneSampleProportion.NIS(alpha=0.05, beta=0.20, p=0.50, delta=0.10, differ=0.05)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesampleproportionnis-059",
      "template": "non_inferiority_1prop",
      "difficulty": "advanced",
      "question": "A orthopedic surgeon is designing a non-inferiority trial for rheumatoid arthritis using a proportion endpoint. The non-inferiority margin is 0.1. At significance level of 0.05 with 90% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_1prop",
      "ground_truth": {
        "sample_size": 720
      },
      "tolerance": {
        "sample_size": 36
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleProportion.NIS",
        "origin": "TrialSize::OneSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "1prop_nis_30_p90"
      },
      "reference_code": "library(TrialSize)\nOneSampleProportion.NIS(alpha=0.05, beta=0.10, p=0.30, delta=0.10, differ=0.05)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesampleproportionequivalence-060",
      "template": "equivalence_1prop",
      "difficulty": "advanced",
      "question": "A gastroenterologist is designing a equivalence trial for breast cancer using a proportion endpoint. The equivalence margin is 0.1. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_1prop",
      "ground_truth": {
        "sample_size": 857
      },
      "tolerance": {
        "sample_size": 43
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleProportion.Equivalence",
        "origin": "TrialSize::OneSampleProportion.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "1prop_equiv_50_delta10"
      },
      "reference_code": "library(TrialSize)\nOneSampleProportion.Equivalence(alpha=0.05, beta=0.20, p=0.50, delta=0.10, differ=0.05)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesampleproportionequivalence-061",
      "template": "equivalence_1prop",
      "difficulty": "advanced",
      "question": "A pulmonologist is designing a equivalence trial for heart failure using a proportion endpoint. The equivalence margin is 0.15. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_1prop",
      "ground_truth": {
        "sample_size": 180
      },
      "tolerance": {
        "sample_size": 9
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleProportion.Equivalence",
        "origin": "TrialSize::OneSampleProportion.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "1prop_equiv_30_delta15"
      },
      "reference_code": "library(TrialSize)\nOneSampleProportion.Equivalence(alpha=0.05, beta=0.20, p=0.30, delta=0.15, differ=0.05)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplesurvivalnis-068",
      "template": "survival_nis",
      "difficulty": "advanced",
      "question": "A educational researcher is designing a survival analysis study for generalized anxiety disorder. At significance level of 0.05 with 80% power, how many patients are needed per group?",
      "expected_template": "survival_nis",
      "ground_truth": {
        "sample_size": 32
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSurvival.NIS",
        "origin": "TrialSize::TwoSampleSurvival.NIS (Chow/Shao/Wang textbook)",
        "variation": "surv_nis_m10v15"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSurvival.NIS(alpha=0.05, beta=0.20, lam1=log(2)/10, lam2=log(2)/15, k=1, ttotal=36, taccrual=24, gamma=0.001, margin=0.02)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplesurvivalnis-069",
      "template": "survival_nis",
      "difficulty": "advanced",
      "question": "A epidemiologist is designing a survival analysis study for osteoarthritis. At significance level of 0.05 with 80% power, how many patients are needed per group?",
      "expected_template": "survival_nis",
      "ground_truth": {
        "sample_size": 19
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSurvival.NIS",
        "origin": "TrialSize::TwoSampleSurvival.NIS (Chow/Shao/Wang textbook)",
        "variation": "surv_nis_lam10v05"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSurvival.NIS(alpha=0.05, beta=0.20, lam1=0.10, lam2=0.05, k=1, ttotal=36, taccrual=24, gamma=0.001, margin=0.02)",
      "tier": 3
    },
    {
      "id": "t3-ts-coxnis-078",
      "template": "cox_nis",
      "difficulty": "advanced",
      "question": "A clinical nutritionist is designing a survival analysis study for COPD. The study expects a large effect size (Cohen's d = 1). At significance level of 0.05 with 80% power, how many patients are needed per group?",
      "expected_template": "cox_nis",
      "ground_truth": {
        "sample_size": 497
      },
      "tolerance": {
        "sample_size": 25
      },
      "source": {
        "package": "TrialSize",
        "function": "Cox.NIS",
        "origin": "TrialSize::Cox.NIS (Chow/Shao/Wang textbook)",
        "variation": "cox_nis_hr15"
      },
      "reference_code": "library(TrialSize)\nCox.NIS(alpha=0.05, beta=0.20, loghr=log(1.5), p1=0.5, d=1, delta=log(1.2))",
      "tier": 3
    },
    {
      "id": "t3-ts-coxnis-079",
      "template": "cox_nis",
      "difficulty": "advanced",
      "question": "A rehabilitation specialist is designing a survival analysis study for rheumatoid arthritis. The study expects a large effect size (Cohen's d = 1). At significance level of 0.05 with 80% power, how many patients are needed per group?",
      "expected_template": "cox_nis",
      "ground_truth": {
        "sample_size": 134
      },
      "tolerance": {
        "sample_size": 7
      },
      "source": {
        "package": "TrialSize",
        "function": "Cox.NIS",
        "origin": "TrialSize::Cox.NIS (Chow/Shao/Wang textbook)",
        "variation": "cox_nis_hr20"
      },
      "reference_code": "library(TrialSize)\nCox.NIS(alpha=0.05, beta=0.20, loghr=log(2.0), p1=0.5, d=1, delta=log(1.3))",
      "tier": 3
    },
    {
      "id": "t3-ts-coxequivalence-080",
      "template": "cox_equivalence",
      "difficulty": "advanced",
      "question": "A occupational therapist is designing a survival analysis study for breast cancer. The study expects a large effect size (Cohen's d = 1). At significance level of 0.05 with 80% power, how many patients are needed per group?",
      "expected_template": "cox_equivalence",
      "ground_truth": {
        "sample_size": 688
      },
      "tolerance": {
        "sample_size": 35
      },
      "source": {
        "package": "TrialSize",
        "function": "Cox.Equivalence",
        "origin": "TrialSize::Cox.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "cox_equiv_hr15"
      },
      "reference_code": "library(TrialSize)\nCox.Equivalence(alpha=0.05, beta=0.20, loghr=log(1.5), p1=0.5, d=1, delta=log(1.2))",
      "tier": 3
    },
    {
      "id": "t3-ts-coxequivalence-081",
      "template": "cox_equivalence",
      "difficulty": "advanced",
      "question": "A speech pathologist is designing a survival analysis study for heart failure. The study expects a large effect size (Cohen's d = 1). At significance level of 0.05 with 80% power, how many patients are needed per group?",
      "expected_template": "cox_equivalence",
      "ground_truth": {
        "sample_size": 185
      },
      "tolerance": {
        "sample_size": 10
      },
      "source": {
        "package": "TrialSize",
        "function": "Cox.Equivalence",
        "origin": "TrialSize::Cox.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "cox_equiv_hr20"
      },
      "reference_code": "library(TrialSize)\nCox.Equivalence(alpha=0.05, beta=0.20, loghr=log(2.0), p1=0.5, d=1, delta=log(1.3))",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequality-082",
      "template": "crossover_2x2",
      "difficulty": "basic",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_2x2",
      "ground_truth": {
        "sample_size": 16
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equality",
        "origin": "TrialSize::TwoSampleCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "cross_eq_sd10_diff5"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equality(alpha=0.05, beta=0.20, sigma=10, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequality-083",
      "template": "crossover_2x2",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_2x2",
      "ground_truth": {
        "sample_size": 22
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equality",
        "origin": "TrialSize::TwoSampleCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "cross_eq_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equality(alpha=0.05, beta=0.10, sigma=10, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequality-084",
      "template": "crossover_2x2",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_2x2",
      "ground_truth": {
        "sample_size": 36
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equality",
        "origin": "TrialSize::TwoSampleCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "cross_eq_sd15"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equality(alpha=0.05, beta=0.20, sigma=15, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequality-085",
      "template": "crossover_2x2",
      "difficulty": "basic",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_2x2",
      "ground_truth": {
        "sample_size": 44
      },
      "tolerance": {
        "sample_size": 3
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equality",
        "origin": "TrialSize::TwoSampleCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "cross_eq_diff3"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equality(alpha=0.05, beta=0.20, sigma=10, margin=3)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequality-086",
      "template": "crossover_2x2",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.01, how many subjects are required?",
      "expected_template": "crossover_2x2",
      "ground_truth": {
        "sample_size": 24
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equality",
        "origin": "TrialSize::TwoSampleCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "cross_eq_a01"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equality(alpha=0.01, beta=0.20, sigma=10, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossovernis-087",
      "template": "crossover_nis",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_nis",
      "ground_truth": {
        "sample_size": 13
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.NIS",
        "origin": "TrialSize::TwoSampleCrossOver.NIS (Chow/Shao/Wang textbook)",
        "variation": "cross_nis_delta0"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.NIS(alpha=0.05, beta=0.20, sigma=10, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossovernis-088",
      "template": "crossover_nis",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_nis",
      "ground_truth": {
        "sample_size": 35
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.NIS",
        "origin": "TrialSize::TwoSampleCrossOver.NIS (Chow/Shao/Wang textbook)",
        "variation": "cross_nis_margin3"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.NIS(alpha=0.05, beta=0.20, sigma=10, delta=0, margin=3)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossovernis-089",
      "template": "crossover_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_nis",
      "ground_truth": {
        "sample_size": 18
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.NIS",
        "origin": "TrialSize::TwoSampleCrossOver.NIS (Chow/Shao/Wang textbook)",
        "variation": "cross_nis_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.NIS(alpha=0.05, beta=0.10, sigma=10, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequivalence-090",
      "template": "crossover_equivalence",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_equivalence",
      "ground_truth": {
        "sample_size": 27
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equivalence",
        "origin": "TrialSize::TwoSampleCrossOver.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "cross_equiv_delta1"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equivalence(alpha=0.05, beta=0.20, sigma=10, delta=1, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequivalence-091",
      "template": "crossover_equivalence",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_equivalence",
      "ground_truth": {
        "sample_size": 48
      },
      "tolerance": {
        "sample_size": 3
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equivalence",
        "origin": "TrialSize::TwoSampleCrossOver.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "cross_equiv_delta2"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equivalence(alpha=0.05, beta=0.20, sigma=10, delta=2, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequivalence-092",
      "template": "crossover_equivalence",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_equivalence",
      "ground_truth": {
        "sample_size": 34
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equivalence",
        "origin": "TrialSize::TwoSampleCrossOver.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "cross_equiv_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equivalence(alpha=0.05, beta=0.10, sigma=10, delta=1, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleseqcrossoverequality-093",
      "template": "seq_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "seq_crossover",
      "ground_truth": {
        "sample_size": 16
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSeqCrossOver.Equality",
        "origin": "TrialSize::TwoSampleSeqCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "seqcross_eq_s2"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSeqCrossOver.Equality(alpha=0.05, beta=0.20, sigma=100, sequence=2, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleseqcrossoverequality-094",
      "template": "seq_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "seq_crossover",
      "ground_truth": {
        "sample_size": 8
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSeqCrossOver.Equality",
        "origin": "TrialSize::TwoSampleSeqCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "seqcross_eq_s4"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSeqCrossOver.Equality(alpha=0.05, beta=0.20, sigma=100, sequence=4, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleseqcrossoverequality-095",
      "template": "seq_crossover",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "seq_crossover",
      "ground_truth": {
        "sample_size": 22
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSeqCrossOver.Equality",
        "origin": "TrialSize::TwoSampleSeqCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "seqcross_eq_p90"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSeqCrossOver.Equality(alpha=0.05, beta=0.10, sigma=100, sequence=2, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleseqcrossovernis-096",
      "template": "seq_crossover_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a higher-order sequential crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "seq_crossover_nis",
      "ground_truth": {
        "sample_size": 13
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSeqCrossOver.NIS",
        "origin": "TrialSize::TwoSampleSeqCrossOver.NIS (Chow/Shao/Wang textbook)",
        "variation": "seqcross_nis_s2"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSeqCrossOver.NIS(alpha=0.05, beta=0.20, sigma=100, sequence=2, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleseqcrossovernis-097",
      "template": "seq_crossover_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a higher-order sequential crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "seq_crossover_nis",
      "ground_truth": {
        "sample_size": 7
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSeqCrossOver.NIS",
        "origin": "TrialSize::TwoSampleSeqCrossOver.NIS (Chow/Shao/Wang textbook)",
        "variation": "seqcross_nis_s4"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSeqCrossOver.NIS(alpha=0.05, beta=0.20, sigma=100, sequence=4, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleseqcrossoverequivalence-098",
      "template": "seq_crossover_equiv",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a higher-order sequential crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "seq_crossover_equiv",
      "ground_truth": {
        "sample_size": 18
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleSeqCrossOver.Equivalence",
        "origin": "TrialSize::TwoSampleSeqCrossOver.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "seqcross_equiv_s2"
      },
      "reference_code": "library(TrialSize)\nTwoSampleSeqCrossOver.Equivalence(alpha=0.05, beta=0.20, sigma=100, sequence=2, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-williamsdesignequality-099",
      "template": "williams_design",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "williams_design",
      "ground_truth": {
        "sample_size": 11
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "WilliamsDesign.Equality",
        "origin": "TrialSize::WilliamsDesign.Equality (Chow/Shao/Wang textbook)",
        "variation": "williams_eq_s3"
      },
      "reference_code": "library(TrialSize)\nWilliamsDesign.Equality(alpha=0.05, beta=0.20, sigma=100, sequence=3, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-williamsdesignequality-100",
      "template": "williams_design",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "williams_design",
      "ground_truth": {
        "sample_size": 16
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "WilliamsDesign.Equality",
        "origin": "TrialSize::WilliamsDesign.Equality (Chow/Shao/Wang textbook)",
        "variation": "williams_eq_s4"
      },
      "reference_code": "library(TrialSize)\nWilliamsDesign.Equality(alpha=0.05, beta=0.20, sigma=200, sequence=4, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-williamsdesignequality-101",
      "template": "williams_design",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "williams_design",
      "ground_truth": {
        "sample_size": 15
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "WilliamsDesign.Equality",
        "origin": "TrialSize::WilliamsDesign.Equality (Chow/Shao/Wang textbook)",
        "variation": "williams_eq_p90"
      },
      "reference_code": "library(TrialSize)\nWilliamsDesign.Equality(alpha=0.05, beta=0.10, sigma=100, sequence=3, delta=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-williamsdesignnis-102",
      "template": "williams_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "williams_nis",
      "ground_truth": {
        "sample_size": 9
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "WilliamsDesign.NIS",
        "origin": "TrialSize::WilliamsDesign.NIS (Chow/Shao/Wang textbook)",
        "variation": "williams_nis_s3"
      },
      "reference_code": "library(TrialSize)\nWilliamsDesign.NIS(alpha=0.05, beta=0.20, sigma=100, sequence=3, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-williamsdesignequivalence-103",
      "template": "williams_equiv",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "williams_equiv",
      "ground_truth": {
        "sample_size": 12
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "WilliamsDesign.Equivalence",
        "origin": "TrialSize::WilliamsDesign.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "williams_equiv_s3"
      },
      "reference_code": "library(TrialSize)\nWilliamsDesign.Equivalence(alpha=0.05, beta=0.20, sigma=100, sequence=3, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignequality-104",
      "template": "mean_williams",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams",
      "ground_truth": {
        "sample_size": 11
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.Equality",
        "origin": "TrialSize::MeanWilliamsDesign.Equality (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_eq_k3"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.Equality(alpha=0.05, beta=0.20, sigma=10, k=3, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignequality-105",
      "template": "mean_williams",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams",
      "ground_truth": {
        "sample_size": 8
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.Equality",
        "origin": "TrialSize::MeanWilliamsDesign.Equality (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_eq_k4"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.Equality(alpha=0.05, beta=0.20, sigma=10, k=4, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignequality-106",
      "template": "mean_williams",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams",
      "ground_truth": {
        "sample_size": 15
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.Equality",
        "origin": "TrialSize::MeanWilliamsDesign.Equality (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_eq_p90"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.Equality(alpha=0.05, beta=0.10, sigma=10, k=3, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignequality-107",
      "template": "mean_williams",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams",
      "ground_truth": {
        "sample_size": 24
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.Equality",
        "origin": "TrialSize::MeanWilliamsDesign.Equality (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_eq_sd15"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.Equality(alpha=0.05, beta=0.20, sigma=15, k=3, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignnis-108",
      "template": "mean_williams_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams_nis",
      "ground_truth": {
        "sample_size": 9
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.NIS",
        "origin": "TrialSize::MeanWilliamsDesign.NIS (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_nis_k3"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.NIS(alpha=0.05, beta=0.20, sigma=10, k=3, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignnis-109",
      "template": "mean_williams_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams_nis",
      "ground_truth": {
        "sample_size": 7
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.NIS",
        "origin": "TrialSize::MeanWilliamsDesign.NIS (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_nis_k4"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.NIS(alpha=0.05, beta=0.20, sigma=10, k=4, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignequivalence-110",
      "template": "mean_williams_equiv",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams_equiv",
      "ground_truth": {
        "sample_size": 12
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.Equivalence",
        "origin": "TrialSize::MeanWilliamsDesign.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_equiv_k3"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.Equivalence(alpha=0.05, beta=0.20, sigma=10, k=3, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-meanwilliamsdesignequivalence-111",
      "template": "mean_williams_equiv",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a Williams design bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "mean_williams_equiv",
      "ground_truth": {
        "sample_size": 9
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "MeanWilliamsDesign.Equivalence",
        "origin": "TrialSize::MeanWilliamsDesign.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mwilliams_equiv_k4"
      },
      "reference_code": "library(TrialSize)\nMeanWilliamsDesign.Equivalence(alpha=0.05, beta=0.20, sigma=10, k=4, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativerisknis-126",
      "template": "relative_risk_nis",
      "difficulty": "advanced",
      "question": "A infectious disease specialist is designing a study comparing event rates for inflammatory bowel disease. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "relative_risk_nis",
      "ground_truth": {
        "sample_size": 730
      },
      "tolerance": {
        "sample_size": 37
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRisk.NIS",
        "origin": "TrialSize::RelativeRisk.NIS (Chow/Shao/Wang textbook)",
        "variation": "rr_nis_15_margin10"
      },
      "reference_code": "library(TrialSize)\nRelativeRisk.NIS(alpha=0.05, beta=0.20, or=1.5, k=1, pt=0.30, pc=0.20, margin=0.10)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativerisknis-127",
      "template": "relative_risk_nis",
      "difficulty": "advanced",
      "question": "A psychologist is designing a study comparing event rates for migraine. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "relative_risk_nis",
      "ground_truth": {
        "sample_size": 219
      },
      "tolerance": {
        "sample_size": 11
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRisk.NIS",
        "origin": "TrialSize::RelativeRisk.NIS (Chow/Shao/Wang textbook)",
        "variation": "rr_nis_20_margin15"
      },
      "reference_code": "library(TrialSize)\nRelativeRisk.NIS(alpha=0.05, beta=0.20, or=2.0, k=1, pt=0.40, pc=0.20, margin=0.15)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskequivalence-128",
      "template": "relative_risk_equiv",
      "difficulty": "advanced",
      "question": "A educational researcher is designing a study comparing event rates for generalized anxiety disorder. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "relative_risk_equiv",
      "ground_truth": {
        "sample_size": 1446
      },
      "tolerance": {
        "sample_size": 73
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRisk.Equivalence",
        "origin": "TrialSize::RelativeRisk.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "rr_equiv_margin15"
      },
      "reference_code": "library(TrialSize)\nRelativeRisk.Equivalence(alpha=0.05, beta=0.20, or=1.5, k=1, pt=0.30, pc=0.20, margin=0.15)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskequivalence-129",
      "template": "relative_risk_equiv",
      "difficulty": "advanced",
      "question": "A epidemiologist is designing a study comparing event rates for osteoarthritis. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "relative_risk_equiv",
      "ground_truth": {
        "sample_size": 367
      },
      "tolerance": {
        "sample_size": 19
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRisk.Equivalence",
        "origin": "TrialSize::RelativeRisk.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "rr_equiv_margin20"
      },
      "reference_code": "library(TrialSize)\nRelativeRisk.Equivalence(alpha=0.05, beta=0.20, or=2.0, k=1, pt=0.40, pc=0.20, margin=0.20)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequality-130",
      "template": "rr_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover",
      "ground_truth": {
        "sample_size": 24
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equality",
        "origin": "TrialSize::RelativeRiskCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "rrcross_eq_sigma05_or15"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equality(alpha=0.05, beta=0.20, sigma=0.5, or=1.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequality-131",
      "template": "rr_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover",
      "ground_truth": {
        "sample_size": 9
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equality",
        "origin": "TrialSize::RelativeRiskCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "rrcross_eq_sigma05_or20"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equality(alpha=0.05, beta=0.20, sigma=0.5, or=2.0)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequality-132",
      "template": "rr_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover",
      "ground_truth": {
        "sample_size": 32
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equality",
        "origin": "TrialSize::RelativeRiskCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "rrcross_eq_p90"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equality(alpha=0.05, beta=0.10, sigma=0.5, or=1.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequality-133",
      "template": "rr_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover",
      "ground_truth": {
        "sample_size": 39
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equality",
        "origin": "TrialSize::RelativeRiskCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "rrcross_eq_sigma08"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equality(alpha=0.05, beta=0.20, sigma=0.8, or=1.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossovernis-134",
      "template": "rr_crossover_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover_nis",
      "ground_truth": {
        "sample_size": 278
      },
      "tolerance": {
        "sample_size": 14
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.NIS",
        "origin": "TrialSize::RelativeRiskCrossOver.NIS (Chow/Shao/Wang textbook)",
        "variation": "rrcross_nis_or15"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.NIS(alpha=0.05, beta=0.20, sigma=0.5, or=1.5, margin=0.3)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossovernis-135",
      "template": "rr_crossover_nis",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover_nis",
      "ground_truth": {
        "sample_size": 83
      },
      "tolerance": {
        "sample_size": 5
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.NIS",
        "origin": "TrialSize::RelativeRiskCrossOver.NIS (Chow/Shao/Wang textbook)",
        "variation": "rrcross_nis_or20"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.NIS(alpha=0.05, beta=0.20, sigma=0.5, or=2.0, margin=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequivalence-136",
      "template": "rr_crossover_equiv",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover_equiv",
      "ground_truth": {
        "sample_size": 385
      },
      "tolerance": {
        "sample_size": 20
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equivalence",
        "origin": "TrialSize::RelativeRiskCrossOver.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "rrcross_equiv_or15"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equivalence(alpha=0.05, beta=0.20, sigma=0.5, or=1.5, margin=0.3)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequivalence-137",
      "template": "rr_crossover_equiv",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence (TOST) study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover_equiv",
      "ground_truth": {
        "sample_size": 115
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equivalence",
        "origin": "TrialSize::RelativeRiskCrossOver.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "rrcross_equiv_or20"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equivalence(alpha=0.05, beta=0.20, sigma=0.5, or=2.0, margin=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-138",
      "template": "bioequivalence_abe",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 4
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma020"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.20, sigma1.1=0.20, delta=0, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-139",
      "template": "bioequivalence_abe",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 5
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma020_p90"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.10, sigma1.1=0.20, delta=0, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-140",
      "template": "bioequivalence_abe",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 8
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma030"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.20, sigma1.1=0.30, delta=0, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-141",
      "template": "bioequivalence_abe",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 13
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma040"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.20, sigma1.1=0.40, delta=0, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-142",
      "template": "bioequivalence_abe",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 20
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma050"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.20, sigma1.1=0.50, delta=0, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-143",
      "template": "bioequivalence_abe",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 9
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma025_delta005"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.20, sigma1.1=0.25, delta=0.05, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-pbe-144",
      "template": "bioequivalence_pbe",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a population bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_pbe",
      "ground_truth": {
        "sample_size": 25
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "PBE",
        "origin": "TrialSize::PBE (Chow/Shao/Wang textbook)",
        "variation": "pbe_rho05"
      },
      "reference_code": "library(TrialSize)\nPBE(alpha=0.05, beta=0.20, sigma1.1=0.20, sigmatt=0.30, sigmatr=0.30, sigmabt=0.20, sigmabr=0.20, rho=0.50, a=1, delta=0.10, lamda=0.10)",
      "tier": 3
    },
    {
      "id": "t3-ts-pbe-145",
      "template": "bioequivalence_pbe",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a population bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_pbe",
      "ground_truth": {
        "sample_size": 20
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "PBE",
        "origin": "TrialSize::PBE (Chow/Shao/Wang textbook)",
        "variation": "pbe_rho06"
      },
      "reference_code": "library(TrialSize)\nPBE(alpha=0.05, beta=0.20, sigma1.1=0.25, sigmatt=0.35, sigmatr=0.35, sigmabt=0.25, sigmabr=0.25, rho=0.60, a=1, delta=0.10, lamda=0.15)",
      "tier": 3
    },
    {
      "id": "t3-ts-pbe-146",
      "template": "bioequivalence_pbe",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a population bioequivalence study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_pbe",
      "ground_truth": {
        "sample_size": 34
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "PBE",
        "origin": "TrialSize::PBE (Chow/Shao/Wang textbook)",
        "variation": "pbe_p90"
      },
      "reference_code": "library(TrialSize)\nPBE(alpha=0.05, beta=0.10, sigma1.1=0.20, sigmatt=0.30, sigmatr=0.30, sigmabt=0.20, sigmabr=0.20, rho=0.50, a=1, delta=0.10, lamda=0.10)",
      "tier": 3
    },
    {
      "id": "t3-ts-carryover-157",
      "template": "carry_over",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a bioequivalence with potential carry-over effects study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "carry_over",
      "ground_truth": {
        "sample_size": 8
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Carry.Over",
        "origin": "TrialSize::Carry.Over (Chow/Shao/Wang textbook)",
        "variation": "carry_s10_s15_g5"
      },
      "reference_code": "library(TrialSize)\nCarry.Over(alpha=0.05, beta=0.20, sigma1=10, sigma2=15, gamma=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-carryover-158",
      "template": "carry_over",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a bioequivalence with potential carry-over effects study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "carry_over",
      "ground_truth": {
        "sample_size": 18
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Carry.Over",
        "origin": "TrialSize::Carry.Over (Chow/Shao/Wang textbook)",
        "variation": "carry_s10_s10_g3"
      },
      "reference_code": "library(TrialSize)\nCarry.Over(alpha=0.05, beta=0.20, sigma1=10, sigma2=10, gamma=3)",
      "tier": 3
    },
    {
      "id": "t3-ts-carryover-159",
      "template": "carry_over",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a bioequivalence with potential carry-over effects study using a 2x2 crossover design. With 90% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "carry_over",
      "ground_truth": {
        "sample_size": 11
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Carry.Over",
        "origin": "TrialSize::Carry.Over (Chow/Shao/Wang textbook)",
        "variation": "carry_p90"
      },
      "reference_code": "library(TrialSize)\nCarry.Over(alpha=0.05, beta=0.10, sigma1=10, sigma2=15, gamma=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-carryover-160",
      "template": "carry_over",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a bioequivalence with potential carry-over effects study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "carry_over",
      "ground_truth": {
        "sample_size": 5
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Carry.Over",
        "origin": "TrialSize::Carry.Over (Chow/Shao/Wang textbook)",
        "variation": "carry_s15_s20_g8"
      },
      "reference_code": "library(TrialSize)\nCarry.Over(alpha=0.05, beta=0.20, sigma1=15, sigma2=20, gamma=8)",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponselinear-161",
      "template": "dose_response_linear",
      "difficulty": "advanced",
      "question": "A social scientist is designing a dose-response study for heart failure measuring continuous response. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_linear",
      "ground_truth": {
        "sample_size": 5
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.Linear",
        "origin": "TrialSize::Dose.Response.Linear (Chow/Shao/Wang textbook)",
        "variation": "dose_linear_4dose"
      },
      "reference_code": "library(TrialSize)\nDose.Response.Linear(alpha=0.05, beta=0.20, sigma=1, mui=c(0,0.5,1.0,1.5), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponselinear-162",
      "template": "dose_response_linear",
      "difficulty": "advanced",
      "question": "A pharmacist researcher is designing a dose-response study for Alzheimer's disease measuring continuous response. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_linear",
      "ground_truth": {
        "sample_size": 5
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.Linear",
        "origin": "TrialSize::Dose.Response.Linear (Chow/Shao/Wang textbook)",
        "variation": "dose_linear_sigma2"
      },
      "reference_code": "library(TrialSize)\nDose.Response.Linear(alpha=0.05, beta=0.20, sigma=2, mui=c(0,1,2,3), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponselinear-163",
      "template": "dose_response_linear",
      "difficulty": "advanced",
      "question": "A gerontologist is designing a dose-response study for Parkinson's disease measuring continuous response. At significance level of 0.05 with 90% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_linear",
      "ground_truth": {
        "sample_size": 7
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.Linear",
        "origin": "TrialSize::Dose.Response.Linear (Chow/Shao/Wang textbook)",
        "variation": "dose_linear_p90"
      },
      "reference_code": "library(TrialSize)\nDose.Response.Linear(alpha=0.05, beta=0.10, sigma=1, mui=c(0,0.5,1.0,1.5), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponsebinary-164",
      "template": "dose_response_binary",
      "difficulty": "advanced",
      "question": "A sports medicine physician is designing a dose-response study for multiple sclerosis measuring binary response. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_binary",
      "ground_truth": {
        "sample_size": 23
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.binary",
        "origin": "TrialSize::Dose.Response.binary (Chow/Shao/Wang textbook)",
        "variation": "dose_binary_4dose"
      },
      "reference_code": "library(TrialSize)\nDose.Response.binary(alpha=0.05, beta=0.20, pi=c(0.10,0.20,0.30,0.40), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponsebinary-165",
      "template": "dose_response_binary",
      "difficulty": "advanced",
      "question": "A allergist is designing a dose-response study for chronic kidney disease measuring binary response. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_binary",
      "ground_truth": {
        "sample_size": 18
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.binary",
        "origin": "TrialSize::Dose.Response.binary (Chow/Shao/Wang textbook)",
        "variation": "dose_binary_steep"
      },
      "reference_code": "library(TrialSize)\nDose.Response.binary(alpha=0.05, beta=0.20, pi=c(0.05,0.10,0.20,0.35), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponsebinary-166",
      "template": "dose_response_binary",
      "difficulty": "advanced",
      "question": "A urologist is designing a dose-response study for inflammatory bowel disease measuring binary response. At significance level of 0.05 with 90% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_binary",
      "ground_truth": {
        "sample_size": 31
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.binary",
        "origin": "TrialSize::Dose.Response.binary (Chow/Shao/Wang textbook)",
        "variation": "dose_binary_p90"
      },
      "reference_code": "library(TrialSize)\nDose.Response.binary(alpha=0.05, beta=0.10, pi=c(0.10,0.20,0.30,0.40), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponsetimetoevent-167",
      "template": "dose_response_tte",
      "difficulty": "advanced",
      "question": "A hematologist is designing a dose-response study for migraine measuring time-to-event. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_tte",
      "ground_truth": {
        "sample_size": 49
      },
      "tolerance": {
        "sample_size": 3
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.time.to.event",
        "origin": "TrialSize::Dose.Response.time.to.event (Chow/Shao/Wang textbook)",
        "variation": "dose_tte_4dose"
      },
      "reference_code": "library(TrialSize)\nDose.Response.time.to.event(alpha=0.05, beta=0.20, T0=12, T=24, Ti=c(12,15,18,24), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-doseresponsetimetoevent-168",
      "template": "dose_response_tte",
      "difficulty": "advanced",
      "question": "A clinical nutritionist is designing a dose-response study for generalized anxiety disorder measuring time-to-event. At significance level of 0.05 with 90% power, how many subjects per dose group are needed?",
      "expected_template": "dose_response_tte",
      "ground_truth": {
        "sample_size": 68
      },
      "tolerance": {
        "sample_size": 4
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Response.time.to.event",
        "origin": "TrialSize::Dose.Response.time.to.event (Chow/Shao/Wang textbook)",
        "variation": "dose_tte_p90"
      },
      "reference_code": "library(TrialSize)\nDose.Response.time.to.event(alpha=0.05, beta=0.10, T0=12, T=24, Ti=c(12,15,18,24), ci=c(-3,-1,1,3), fi=c(1,1,1,1))",
      "tier": 3
    },
    {
      "id": "t3-ts-dosemineffect-169",
      "template": "dose_min_effect",
      "difficulty": "intermediate",
      "question": "A rehabilitation specialist is designing a dose-response study for osteoarthritis measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_min_effect",
      "ground_truth": {
        "sample_size": 10
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Min.Effect",
        "origin": "TrialSize::Dose.Min.Effect (Chow/Shao/Wang textbook)",
        "variation": "dose_min_qt25"
      },
      "reference_code": "library(TrialSize)\nDose.Min.Effect(alpha=0.05, beta=0.20, qt=0.25, sigma=1, delta=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-dosemineffect-170",
      "template": "dose_min_effect",
      "difficulty": "intermediate",
      "question": "A occupational therapist is designing a dose-response study for atrial fibrillation measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_min_effect",
      "ground_truth": {
        "sample_size": 15
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Min.Effect",
        "origin": "TrialSize::Dose.Min.Effect (Chow/Shao/Wang textbook)",
        "variation": "dose_min_qt50"
      },
      "reference_code": "library(TrialSize)\nDose.Min.Effect(alpha=0.05, beta=0.20, qt=0.50, sigma=1, delta=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-dosemineffect-171",
      "template": "dose_min_effect",
      "difficulty": "advanced",
      "question": "A speech pathologist is designing a dose-response study for psoriasis measuring the primary endpoint. At significance level of 0.05 with 90% power, how many subjects per dose group are needed?",
      "expected_template": "dose_min_effect",
      "ground_truth": {
        "sample_size": 19
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Min.Effect",
        "origin": "TrialSize::Dose.Min.Effect (Chow/Shao/Wang textbook)",
        "variation": "dose_min_p90"
      },
      "reference_code": "library(TrialSize)\nDose.Min.Effect(alpha=0.05, beta=0.10, qt=0.25, sigma=1, delta=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-dosemineffect-172",
      "template": "dose_min_effect",
      "difficulty": "intermediate",
      "question": "A physical therapist is designing a dose-response study for epilepsy measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_min_effect",
      "ground_truth": {
        "sample_size": 10
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Min.Effect",
        "origin": "TrialSize::Dose.Min.Effect (Chow/Shao/Wang textbook)",
        "variation": "dose_min_sigma2"
      },
      "reference_code": "library(TrialSize)\nDose.Min.Effect(alpha=0.05, beta=0.20, qt=0.25, sigma=2, delta=1.0)",
      "tier": 3
    },
    {
      "id": "t3-ts-qtpkparallel-202",
      "template": "qt_pk_parallel",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a parallel-group TQT (thorough QT) study. The expected QTc prolongation effect is specified. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "qt_pk_parallel",
      "ground_truth": {
        "sample_size": 117
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "TrialSize",
        "function": "QT.PK.parallel",
        "origin": "TrialSize::QT.PK.parallel (Chow/Shao/Wang textbook)",
        "variation": "qtpk_par_K3"
      },
      "reference_code": "library(TrialSize)\nQT.PK.parallel(alpha=0.05, beta=0.20, pho=0.50, K=3, delta=0.30, v1=1, v2=1, tau1=0.5, tau2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-qtpkparallel-203",
      "template": "qt_pk_parallel",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a parallel-group TQT (thorough QT) study. The expected QTc prolongation effect is specified. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "qt_pk_parallel",
      "ground_truth": {
        "sample_size": 110
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "TrialSize",
        "function": "QT.PK.parallel",
        "origin": "TrialSize::QT.PK.parallel (Chow/Shao/Wang textbook)",
        "variation": "qtpk_par_K4"
      },
      "reference_code": "library(TrialSize)\nQT.PK.parallel(alpha=0.05, beta=0.20, pho=0.50, K=4, delta=0.30, v1=1, v2=1, tau1=0.5, tau2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-qtpkparallel-204",
      "template": "qt_pk_parallel",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a parallel-group TQT (thorough QT) study. The expected QTc prolongation effect is specified. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "qt_pk_parallel",
      "ground_truth": {
        "sample_size": 42
      },
      "tolerance": {
        "sample_size": 3
      },
      "source": {
        "package": "TrialSize",
        "function": "QT.PK.parallel",
        "origin": "TrialSize::QT.PK.parallel (Chow/Shao/Wang textbook)",
        "variation": "qtpk_par_d05"
      },
      "reference_code": "library(TrialSize)\nQT.PK.parallel(alpha=0.05, beta=0.20, pho=0.50, K=3, delta=0.50, v1=1, v2=1, tau1=0.5, tau2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-qtpkcrossover-205",
      "template": "qt_pk_crossover",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "qt_pk_crossover",
      "ground_truth": {
        "sample_size": 22
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "QT.PK.crossover",
        "origin": "TrialSize::QT.PK.crossover (Chow/Shao/Wang textbook)",
        "variation": "qtpk_cross_K3"
      },
      "reference_code": "library(TrialSize)\nQT.PK.crossover(alpha=0.05, beta=0.20, pho=0.50, K=3, delta=0.50, gamma=0.001, v1=1, v2=1, tau1=0.5, tau2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-qtpkcrossover-206",
      "template": "qt_pk_crossover",
      "difficulty": "advanced",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "qt_pk_crossover",
      "ground_truth": {
        "sample_size": 21
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "QT.PK.crossover",
        "origin": "TrialSize::QT.PK.crossover (Chow/Shao/Wang textbook)",
        "variation": "qtpk_cross_K4"
      },
      "reference_code": "library(TrialSize)\nQT.PK.crossover(alpha=0.05, beta=0.20, pho=0.50, K=4, delta=0.50, gamma=0.001, v1=1, v2=1, tau1=0.5, tau2=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-propensityscorenostrata-212",
      "template": "propensity_nostrata",
      "difficulty": "advanced",
      "question": "A rheumatologist is conducting an observational study using propensity score methods to estimate a treatment effect. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "propensity_nostrata",
      "ground_truth": {
        "sample_size": 2584
      },
      "tolerance": {
        "sample_size": 130
      },
      "source": {
        "package": "TrialSize",
        "function": "Propensity.Score.nostrata",
        "origin": "TrialSize::Propensity.Score.nostrata (Chow/Shao/Wang textbook)",
        "variation": "prop_ns_phi15"
      },
      "reference_code": "library(TrialSize)\nPropensity.Score.nostrata(alpha=0.05, beta=0.20, J=2, a=c(0.5,0.5), b=c(0.3,0.7), p1=c(0.30,0.40), phi=1.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-propensityscorenostrata-213",
      "template": "propensity_nostrata",
      "difficulty": "advanced",
      "question": "A dermatologist is conducting an observational study using propensity score methods to estimate a treatment effect. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "propensity_nostrata",
      "ground_truth": {
        "sample_size": 692
      },
      "tolerance": {
        "sample_size": 35
      },
      "source": {
        "package": "TrialSize",
        "function": "Propensity.Score.nostrata",
        "origin": "TrialSize::Propensity.Score.nostrata (Chow/Shao/Wang textbook)",
        "variation": "prop_ns_phi20_J3"
      },
      "reference_code": "library(TrialSize)\nPropensity.Score.nostrata(alpha=0.05, beta=0.20, J=3, a=c(0.3,0.3,0.4), b=c(0.3,0.5,0.7), p1=c(0.25,0.35,0.45), phi=2.0)",
      "tier": 3
    },
    {
      "id": "t3-ts-propensityscorestrata-214",
      "template": "propensity_strata",
      "difficulty": "advanced",
      "question": "A ophthalmologist is conducting an observational study using propensity score methods to estimate a treatment effect. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "propensity_strata",
      "ground_truth": {
        "sample_size": 967
      },
      "tolerance": {
        "sample_size": 49
      },
      "source": {
        "package": "TrialSize",
        "function": "Propensity.Score.strata",
        "origin": "TrialSize::Propensity.Score.strata (Chow/Shao/Wang textbook)",
        "variation": "prop_st_phi15"
      },
      "reference_code": "library(TrialSize)\nPropensity.Score.strata(alpha=0.05, beta=0.20, J=2, a=c(0.5,0.5), b=c(0.3,0.7), p1=c(0.30,0.40), phi=1.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-propensityscorestrata-215",
      "template": "propensity_strata",
      "difficulty": "advanced",
      "question": "A nephrologist is conducting an observational study using propensity score methods to estimate a treatment effect. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "propensity_strata",
      "ground_truth": {
        "sample_size": 314
      },
      "tolerance": {
        "sample_size": 16
      },
      "source": {
        "package": "TrialSize",
        "function": "Propensity.Score.strata",
        "origin": "TrialSize::Propensity.Score.strata (Chow/Shao/Wang textbook)",
        "variation": "prop_st_phi20_J3"
      },
      "reference_code": "library(TrialSize)\nPropensity.Score.strata(alpha=0.05, beta=0.20, J=3, a=c(0.3,0.3,0.4), b=c(0.3,0.5,0.7), p1=c(0.25,0.35,0.45), phi=2.0)",
      "tier": 3
    },
    {
      "id": "t3-ts-abwithdescalation-216",
      "template": "dose_escalation_ab",
      "difficulty": "advanced",
      "question": "A infectious disease specialist is designing a dose-response study for chronic pain measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_escalation_ab",
      "ground_truth": {
        "total_expected_patients": 5
      },
      "tolerance": {
        "total_expected_patients": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "AB.withDescalation",
        "origin": "TrialSize::AB.withDescalation (Chow/Shao/Wang textbook)",
        "variation": "ab_desc_4dose"
      },
      "reference_code": "library(TrialSize)\nsum(AB.withDescalation(A=3, B=3, C=1, D=2, E=2, DLT=c(0.10, 0.20, 0.30, 0.40)))",
      "tier": 3
    },
    {
      "id": "t3-ts-abwithdescalation-217",
      "template": "dose_escalation_ab",
      "difficulty": "advanced",
      "question": "A psychologist is designing a dose-response study for asthma measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_escalation_ab",
      "ground_truth": {
        "total_expected_patients": 12
      },
      "tolerance": {
        "total_expected_patients": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "AB.withDescalation",
        "origin": "TrialSize::AB.withDescalation (Chow/Shao/Wang textbook)",
        "variation": "ab_desc_5dose"
      },
      "reference_code": "library(TrialSize)\nsum(AB.withDescalation(A=3, B=3, C=1, D=2, E=2, DLT=c(0.05, 0.10, 0.20, 0.30, 0.40)))",
      "tier": 3
    },
    {
      "id": "t3-ts-abwithoutdescalation-218",
      "template": "dose_escalation_ab",
      "difficulty": "advanced",
      "question": "A educational researcher is designing a dose-response study for COPD measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_escalation_ab",
      "ground_truth": {
        "total_expected_patients": 6
      },
      "tolerance": {
        "total_expected_patients": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "AB.withoutDescalation",
        "origin": "TrialSize::AB.withoutDescalation (Chow/Shao/Wang textbook)",
        "variation": "ab_nodesc_4dose"
      },
      "reference_code": "library(TrialSize)\nsum(AB.withoutDescalation(A=3, B=3, C=1, D=2, E=2, DLT=c(0.10, 0.20, 0.30, 0.40)))",
      "tier": 3
    },
    {
      "id": "t3-ts-abwithoutdescalation-219",
      "template": "dose_escalation_ab",
      "difficulty": "advanced",
      "question": "A epidemiologist is designing a dose-response study for rheumatoid arthritis measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_escalation_ab",
      "ground_truth": {
        "total_expected_patients": 8
      },
      "tolerance": {
        "total_expected_patients": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "AB.withoutDescalation",
        "origin": "TrialSize::AB.withoutDescalation (Chow/Shao/Wang textbook)",
        "variation": "ab_nodesc_5dose"
      },
      "reference_code": "library(TrialSize)\nsum(AB.withoutDescalation(A=3, B=3, C=1, D=2, E=2, DLT=c(0.05, 0.10, 0.20, 0.30, 0.40)))",
      "tier": 3
    },
    {
      "id": "t3-ts-intersvnis-220",
      "template": "inter_sv_nis",
      "difficulty": "advanced",
      "question": "A nurse researcher is planning a study using inter sv nis. At significance level of 0.05 with 80% power, what sample size is required?",
      "expected_template": "inter_sv_nis",
      "ground_truth": {
        "sample_size": 36
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "InterSV.NIS",
        "origin": "TrialSize::InterSV.NIS (Chow/Shao/Wang textbook)",
        "variation": "intersv_nis_m3"
      },
      "reference_code": "library(TrialSize)\nInterSV.NIS(alpha=0.05, beta=0.20, vbt=0.30, vwt=0.20, vbr=0.30, vwr=0.20, m=3, margin=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-iscvnis-224",
      "template": "iscv_nis",
      "difficulty": "advanced",
      "question": "A social scientist is planning a study using iscv nis. At significance level of 0.05 with 80% power, what sample size is required?",
      "expected_template": "iscv_nis",
      "ground_truth": {
        "sample_size": 2
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ISCV.NIS",
        "origin": "TrialSize::ISCV.NIS (Chow/Shao/Wang textbook)",
        "variation": "iscv_nis_cv30"
      },
      "reference_code": "library(TrialSize)\nISCV.NIS(alpha=0.05, beta=0.20, CVt=0.30, CVr=0.30, m=3, margin=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-iscvequivalence-225",
      "template": "iscv_equivalence",
      "difficulty": "advanced",
      "question": "A pharmacist researcher is designing a equivalence trial for Alzheimer's disease using the primary endpoint. The equivalence margin is 0.5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "iscv_equivalence",
      "ground_truth": {
        "sample_size": 2
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ISCV.Equivalence",
        "origin": "TrialSize::ISCV.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "iscv_equiv_cv30"
      },
      "reference_code": "library(TrialSize)\nISCV.Equivalence(alpha=0.05, beta=0.20, CVt=0.30, CVr=0.30, m=3, margin=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-254",
      "template": "bioequivalence_abe",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 10
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma035"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.20, sigma1.1=0.35, delta=0, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-abe-255",
      "template": "bioequivalence_abe",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a average bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "bioequivalence_abe",
      "ground_truth": {
        "sample_size": 5
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "ABE",
        "origin": "TrialSize::ABE (Chow/Shao/Wang textbook)",
        "variation": "abe_sigma025"
      },
      "reference_code": "library(TrialSize)\nABE(alpha=0.05, beta=0.20, sigma1.1=0.25, delta=0, epsilon=log(1.25))",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequality-256",
      "template": "crossover_2x2",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_2x2",
      "ground_truth": {
        "sample_size": 63
      },
      "tolerance": {
        "sample_size": 4
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equality",
        "origin": "TrialSize::TwoSampleCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "cross_eq_sd20_diff5"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equality(alpha=0.05, beta=0.20, sigma=20, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplecrossoverequality-257",
      "template": "crossover_2x2",
      "difficulty": "basic",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "crossover_2x2",
      "ground_truth": {
        "sample_size": 7
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleCrossOver.Equality",
        "origin": "TrialSize::TwoSampleCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "cross_eq_diff8"
      },
      "reference_code": "library(TrialSize)\nTwoSampleCrossOver.Equality(alpha=0.05, beta=0.20, sigma=10, margin=8)",
      "tier": 3
    },
    {
      "id": "t3-ts-carryover-258",
      "template": "carry_over",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a bioequivalence with potential carry-over effects study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "carry_over",
      "ground_truth": {
        "sample_size": 4
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Carry.Over",
        "origin": "TrialSize::Carry.Over (Chow/Shao/Wang textbook)",
        "variation": "carry_s20_g10"
      },
      "reference_code": "library(TrialSize)\nCarry.Over(alpha=0.05, beta=0.20, sigma1=20, sigma2=20, gamma=10)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-259",
      "template": "non_inferiority_mean",
      "difficulty": "intermediate",
      "question": "A pharmacist researcher is designing a non-inferiority trial for epilepsy using a continuous endpoint. The non-inferiority margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_mean",
      "ground_truth": {
        "sample_size": 75
      },
      "tolerance": {
        "sample_size": 4
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_nis_k2"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.05, beta=0.20, sigma=10, k=2, delta=0, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeannis-260",
      "template": "superiority_mean",
      "difficulty": "advanced",
      "question": "A gerontologist is designing a superiority trial for hypertension using a continuous endpoint. The superiority margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "superiority_mean",
      "ground_truth": {
        "sample_size": 310
      },
      "tolerance": {
        "sample_size": 16
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.NIS",
        "origin": "TrialSize::TwoSampleMean.NIS (Chow/Shao/Wang textbook)",
        "variation": "mean_sup_sd15_delta2"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.NIS(alpha=0.05, beta=0.20, sigma=15, k=1, delta=2, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosamplemeanequivalence-261",
      "template": "equivalence_mean",
      "difficulty": "advanced",
      "question": "A sports medicine physician is designing a equivalence trial for type 2 diabetes using a continuous endpoint. The equivalence margin is 5. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "equivalence_mean",
      "ground_truth": {
        "sample_size": 108
      },
      "tolerance": {
        "sample_size": 6
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleMean.Equivalence",
        "origin": "TrialSize::TwoSampleMean.Equivalence (Chow/Shao/Wang textbook)",
        "variation": "mean_equiv_delta1"
      },
      "reference_code": "library(TrialSize)\nTwoSampleMean.Equivalence(alpha=0.05, beta=0.20, sigma=10, k=1, delta=1, margin=5)",
      "tier": 3
    },
    {
      "id": "t3-ts-dosemineffect-262",
      "template": "dose_min_effect",
      "difficulty": "intermediate",
      "question": "A allergist is designing a dose-response study for major depressive disorder measuring the primary endpoint. At significance level of 0.05 with 80% power, how many subjects per dose group are needed?",
      "expected_template": "dose_min_effect",
      "ground_truth": {
        "sample_size": 11
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "Dose.Min.Effect",
        "origin": "TrialSize::Dose.Min.Effect (Chow/Shao/Wang textbook)",
        "variation": "dose_min_qt33"
      },
      "reference_code": "library(TrialSize)\nDose.Min.Effect(alpha=0.05, beta=0.20, qt=0.33, sigma=1, delta=0.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequality-263",
      "template": "rr_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover",
      "ground_truth": {
        "sample_size": 15
      },
      "tolerance": {
        "sample_size": 2
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equality",
        "origin": "TrialSize::RelativeRiskCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "rrcross_eq_sigma03"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equality(alpha=0.05, beta=0.20, sigma=0.3, or=1.5)",
      "tier": 3
    },
    {
      "id": "t3-ts-relativeriskcrossoverequality-264",
      "template": "rr_crossover",
      "difficulty": "intermediate",
      "question": "A pharmaceutical company is planning a crossover bioequivalence study using a 2x2 crossover design. With 80% power at significance level of 0.05, how many subjects are required?",
      "expected_template": "rr_crossover",
      "ground_truth": {
        "sample_size": 58
      },
      "tolerance": {
        "sample_size": 3
      },
      "source": {
        "package": "TrialSize",
        "function": "RelativeRiskCrossOver.Equality",
        "origin": "TrialSize::RelativeRiskCrossOver.Equality (Chow/Shao/Wang textbook)",
        "variation": "rrcross_eq_or13"
      },
      "reference_code": "library(TrialSize)\nRelativeRiskCrossOver.Equality(alpha=0.05, beta=0.20, sigma=0.5, or=1.3)",
      "tier": 3
    },
    {
      "id": "t3-ts-twosampleproportionnis-266",
      "template": "non_inferiority_prop",
      "difficulty": "advanced",
      "question": "A rehabilitation specialist is designing a non-inferiority trial for rheumatoid arthritis using a proportion endpoint. The non-inferiority margin is 0.1. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_prop",
      "ground_truth": {
        "sample_size": 297
      },
      "tolerance": {
        "sample_size": 15
      },
      "source": {
        "package": "TrialSize",
        "function": "TwoSampleProportion.NIS",
        "origin": "TrialSize::TwoSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "prop_nis_40_margin10"
      },
      "reference_code": "library(TrialSize)\nTwoSampleProportion.NIS(alpha=0.05, beta=0.20, p1=0.40, p2=0.40, k=1, delta=0, margin=0.10)",
      "tier": 3
    },
    {
      "id": "t3-ts-onesampleproportionnis-268",
      "template": "non_inferiority_1prop",
      "difficulty": "intermediate",
      "question": "A speech pathologist is designing a non-inferiority trial for heart failure using a proportion endpoint. The non-inferiority margin is 0.15. At significance level of 0.05 with 80% power, how many subjects per group are needed?",
      "expected_template": "non_inferiority_1prop",
      "ground_truth": {
        "sample_size": 155
      },
      "tolerance": {
        "sample_size": 8
      },
      "source": {
        "package": "TrialSize",
        "function": "OneSampleProportion.NIS",
        "origin": "TrialSize::OneSampleProportion.NIS (Chow/Shao/Wang textbook)",
        "variation": "1prop_nis_50_delta15"
      },
      "reference_code": "library(TrialSize)\nOneSampleProportion.NIS(alpha=0.05, beta=0.20, p=0.50, delta=0.15, differ=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt2arm-123",
      "template": "cluster_rct_2arm",
      "difficulty": "intermediate",
      "question": "A oncologist is designing a 2-arm cluster randomized trial for multiple sclerosis. The intraclass correlation (ICC) is 0.05. Expecting a medium effect size (Cohen's f = 0.25). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_2arm",
      "ground_truth": {
        "sample_size": 169,
        "power": 0.8,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 4,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt2arm",
        "origin": "WebPower::wp.crt2arm CRAN documentation",
        "variation": "crt2_f025_J30_icc05"
      },
      "reference_code": "library(WebPower)\nwp.crt2arm(f=0.25, J=30, icc=0.05, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt2arm-124",
      "template": "cluster_rct_2arm",
      "difficulty": "intermediate",
      "question": "A neurologist is designing a 2-arm cluster randomized trial for chronic kidney disease. The intraclass correlation (ICC) is 0.05. Expecting a large effect size (Cohen's f = 0.5). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_2arm",
      "ground_truth": {
        "sample_size": 11,
        "power": 0.8,
        "effect_size_f": 0.5
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.01
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt2arm",
        "origin": "WebPower::wp.crt2arm CRAN documentation",
        "variation": "crt2_f050_J20_icc05"
      },
      "reference_code": "library(WebPower)\nwp.crt2arm(f=0.50, J=20, icc=0.05, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt2arm-125",
      "template": "cluster_rct_2arm",
      "difficulty": "intermediate",
      "question": "A psychiatrist is designing a 2-arm cluster randomized trial for inflammatory bowel disease. The intraclass correlation (ICC) is 0.05. Expecting a medium effect size (Cohen's f = 0.25). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_2arm",
      "ground_truth": {
        "sample_size": 21,
        "power": 0.8,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt2arm",
        "origin": "WebPower::wp.crt2arm CRAN documentation",
        "variation": "crt2_f025_J50_icc05"
      },
      "reference_code": "library(WebPower)\nwp.crt2arm(f=0.25, J=50, icc=0.05, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt2arm-126",
      "template": "cluster_rct_2arm",
      "difficulty": "advanced",
      "question": "A pediatrician is designing a 2-arm cluster randomized trial for migraine. The intraclass correlation (ICC) is 0.05. Expecting a medium effect size (Cohen's f = 0.3). At significance level of 0.05 with 90% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_2arm",
      "ground_truth": {
        "sample_size": 97,
        "power": 0.9,
        "effect_size_f": 0.3
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.018,
        "effect_size_f": 0.006
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt2arm",
        "origin": "WebPower::wp.crt2arm CRAN documentation",
        "variation": "crt2_f030_J30_p90"
      },
      "reference_code": "library(WebPower)\nwp.crt2arm(f=0.30, J=30, icc=0.05, power=0.90, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt2arm-127",
      "template": "cluster_rct_2arm",
      "difficulty": "intermediate",
      "question": "A endocrinologist is designing a 2-arm cluster randomized trial for generalized anxiety disorder. The intraclass correlation (ICC) is 0.1. Expecting a large effect size (Cohen's f = 0.5). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_2arm",
      "ground_truth": {
        "sample_size": 8,
        "power": 0.8,
        "effect_size_f": 0.5
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.01
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt2arm",
        "origin": "WebPower::wp.crt2arm CRAN documentation",
        "variation": "crt2_f050_J30_icc10"
      },
      "reference_code": "library(WebPower)\nwp.crt2arm(f=0.50, J=30, icc=0.10, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt2arm-128",
      "template": "cluster_rct_2arm",
      "difficulty": "intermediate",
      "question": "A orthopedic surgeon has 25 participants per group clusters in a 2-arm cluster RCT for osteoarthritis. Each cluster has approximately 25 subjects. The intraclass correlation (ICC) is 0.05. What power is achieved at significance level of 0.05?",
      "expected_template": "cluster_rct_2arm",
      "ground_truth": {
        "sample_size": 25,
        "power": 0.6058,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.0121,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt2arm",
        "origin": "WebPower::wp.crt2arm CRAN documentation",
        "variation": "crt2_n25_J30_pwr"
      },
      "reference_code": "library(WebPower)\nwp.crt2arm(n=25, f=0.25, J=30, icc=0.05, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt2arm-129",
      "template": "cluster_rct_2arm",
      "difficulty": "intermediate",
      "question": "A gastroenterologist has 50 participants per group clusters in a 2-arm cluster RCT for atrial fibrillation. Each cluster has approximately 50 subjects. The intraclass correlation (ICC) is 0.1. What power is achieved at significance level of 0.05?",
      "expected_template": "cluster_rct_2arm",
      "ground_truth": {
        "sample_size": 50,
        "power": 0.6114,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.0122,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt2arm",
        "origin": "WebPower::wp.crt2arm CRAN documentation",
        "variation": "crt2_n50_J40_pwr"
      },
      "reference_code": "library(WebPower)\nwp.crt2arm(n=50, f=0.25, J=40, icc=0.10, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt3arm-130",
      "template": "cluster_rct_3arm",
      "difficulty": "intermediate",
      "question": "A pulmonologist is designing a 3-arm cluster randomized trial for psoriasis. The intraclass correlation (ICC) is 0.05. Expecting a medium effect size (Cohen's f = 0.25). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_3arm",
      "ground_truth": {
        "sample_size": 28,
        "power": 0.8,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt3arm",
        "origin": "WebPower::wp.crt3arm CRAN documentation",
        "variation": "crt3_f025_J50_icc05"
      },
      "reference_code": "library(WebPower)\nwp.crt3arm(f=0.25, J=50, icc=0.05, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt3arm-131",
      "template": "cluster_rct_3arm",
      "difficulty": "intermediate",
      "question": "A rheumatologist is designing a 3-arm cluster randomized trial for epilepsy. The intraclass correlation (ICC) is 0.05. Expecting a large effect size (Cohen's f = 0.4). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_3arm",
      "ground_truth": {
        "sample_size": 13,
        "power": 0.8,
        "effect_size_f": 0.4
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.008
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt3arm",
        "origin": "WebPower::wp.crt3arm CRAN documentation",
        "variation": "crt3_f040_J30_icc05"
      },
      "reference_code": "library(WebPower)\nwp.crt3arm(f=0.40, J=30, icc=0.05, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt3arm-132",
      "template": "cluster_rct_3arm",
      "difficulty": "advanced",
      "question": "A dermatologist is designing a 3-arm cluster randomized trial for hypertension. The intraclass correlation (ICC) is 0.1. Expecting a medium effect size (Cohen's f = 0.25). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_3arm",
      "ground_truth": {
        "sample_size": 346,
        "power": 0.8,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 7,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt3arm",
        "origin": "WebPower::wp.crt3arm CRAN documentation",
        "variation": "crt3_f025_J60_icc10"
      },
      "reference_code": "library(WebPower)\nwp.crt3arm(f=0.25, J=60, icc=0.10, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt3arm-133",
      "template": "cluster_rct_3arm",
      "difficulty": "intermediate",
      "question": "A ophthalmologist is designing a 3-arm cluster randomized trial for type 2 diabetes. The intraclass correlation (ICC) is 0.05. Expecting a large effect size (Cohen's f = 0.5). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "cluster_rct_3arm",
      "ground_truth": {
        "sample_size": 5,
        "power": 0.8,
        "effect_size_f": 0.5
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.01
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt3arm",
        "origin": "WebPower::wp.crt3arm CRAN documentation",
        "variation": "crt3_f050_J40_icc05"
      },
      "reference_code": "library(WebPower)\nwp.crt3arm(f=0.50, J=40, icc=0.05, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-crt3arm-134",
      "template": "cluster_rct_3arm",
      "difficulty": "intermediate",
      "question": "A nephrologist has 30 participants per group clusters in a 3-arm cluster RCT for major depressive disorder. Each cluster has approximately 30 subjects. The intraclass correlation (ICC) is 0.05. What power is achieved at significance level of 0.05?",
      "expected_template": "cluster_rct_3arm",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.8149,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.0163,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.crt3arm",
        "origin": "WebPower::wp.crt3arm CRAN documentation",
        "variation": "crt3_n30_J50_pwr"
      },
      "reference_code": "library(WebPower)\nwp.crt3arm(n=30, f=0.25, J=50, icc=0.05, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt2arm-135",
      "template": "multisite_rct_2arm",
      "difficulty": "intermediate",
      "question": "A infectious disease specialist is designing a 2-arm cluster randomized trial for chronic pain. Expecting a medium effect size (Cohen's f = 0.25). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "multisite_rct_2arm",
      "ground_truth": {
        "sample_size": 33,
        "power": 0.8,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt2arm",
        "origin": "WebPower::wp.mrt2arm CRAN documentation",
        "variation": "mrt2_f025_J30_tau01"
      },
      "reference_code": "library(WebPower)\nwp.mrt2arm(f=0.25, J=30, tau00=0.10, tau11=0.10, sg2=1.0, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt2arm-136",
      "template": "multisite_rct_2arm",
      "difficulty": "intermediate",
      "question": "A psychologist is designing a 2-arm cluster randomized trial for asthma. Expecting a medium effect size (Cohen's f = 0.25). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "multisite_rct_2arm",
      "ground_truth": {
        "sample_size": 13,
        "power": 0.8,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt2arm",
        "origin": "WebPower::wp.mrt2arm CRAN documentation",
        "variation": "mrt2_f025_J50_tau005"
      },
      "reference_code": "library(WebPower)\nwp.mrt2arm(f=0.25, J=50, tau00=0.05, tau11=0.05, sg2=1.0, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt2arm-137",
      "template": "multisite_rct_2arm",
      "difficulty": "advanced",
      "question": "A educational researcher is designing a 2-arm cluster randomized trial for COPD. Expecting a medium effect size (Cohen's f = 0.3). At significance level of 0.05 with 90% power, how many clusters per arm are needed?",
      "expected_template": "multisite_rct_2arm",
      "ground_truth": {
        "sample_size": 29,
        "power": 0.9,
        "effect_size_f": 0.3
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.018,
        "effect_size_f": 0.006
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt2arm",
        "origin": "WebPower::wp.mrt2arm CRAN documentation",
        "variation": "mrt2_f030_J30_p90"
      },
      "reference_code": "library(WebPower)\nwp.mrt2arm(f=0.30, J=30, tau00=0.10, tau11=0.10, sg2=1.0, power=0.90, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt2arm-138",
      "template": "multisite_rct_2arm",
      "difficulty": "intermediate",
      "question": "A epidemiologist is designing a 2-arm cluster randomized trial for rheumatoid arthritis. Expecting a large effect size (Cohen's f = 0.5). At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "multisite_rct_2arm",
      "ground_truth": {
        "sample_size": 9,
        "power": 0.8,
        "effect_size_f": 0.5
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "effect_size_f": 0.01
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt2arm",
        "origin": "WebPower::wp.mrt2arm CRAN documentation",
        "variation": "mrt2_f050_J20"
      },
      "reference_code": "library(WebPower)\nwp.mrt2arm(f=0.50, J=20, tau00=0.10, tau11=0.10, sg2=1.0, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt2arm-139",
      "template": "multisite_rct_2arm",
      "difficulty": "intermediate",
      "question": "A nurse researcher has 30 participants per group clusters in a 2-arm cluster RCT for breast cancer. Each cluster has approximately 30 subjects. What power is achieved at significance level of 0.05?",
      "expected_template": "multisite_rct_2arm",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.7823,
        "effect_size_f": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.0156,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt2arm",
        "origin": "WebPower::wp.mrt2arm CRAN documentation",
        "variation": "mrt2_n30_J30_pwr"
      },
      "reference_code": "library(WebPower)\nwp.mrt2arm(n=30, f=0.25, J=30, tau00=0.10, tau11=0.10, sg2=1.0, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt3arm-140",
      "template": "multisite_rct_3arm",
      "difficulty": "advanced",
      "question": "A social scientist is designing a 3-arm cluster randomized trial for heart failure. Expecting an effect size of f\u00b2 = 0.25. At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "multisite_rct_3arm",
      "ground_truth": {
        "sample_size": 62,
        "power": 0.8,
        "f2": 0.25
      },
      "tolerance": {
        "sample_size": 2,
        "power": 0.016,
        "f2": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt3arm",
        "origin": "WebPower::wp.mrt3arm CRAN documentation",
        "variation": "mrt3_f025_J30"
      },
      "reference_code": "library(WebPower)\nwp.mrt3arm(f1=0.25, f2=0.25, J=30, tau=0.10, sg2=1.0, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt3arm-141",
      "template": "multisite_rct_3arm",
      "difficulty": "advanced",
      "question": "A pharmacist researcher is designing a 3-arm cluster randomized trial for Alzheimer's disease. Expecting an effect size of f\u00b2 = 0.2. At significance level of 0.05 with 80% power, how many clusters per arm are needed?",
      "expected_template": "multisite_rct_3arm",
      "ground_truth": {
        "sample_size": 13,
        "power": 0.8,
        "f2": 0.2
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.016,
        "f2": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt3arm",
        "origin": "WebPower::wp.mrt3arm CRAN documentation",
        "variation": "mrt3_f030f020_J40"
      },
      "reference_code": "library(WebPower)\nwp.mrt3arm(f1=0.30, f2=0.20, J=40, tau=0.05, sg2=1.0, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-mrt3arm-142",
      "template": "multisite_rct_3arm",
      "difficulty": "advanced",
      "question": "A gerontologist has 30 participants per group clusters in a 3-arm cluster RCT for Parkinson's disease. Each cluster has approximately 30 subjects. What power is achieved at significance level of 0.05?",
      "expected_template": "multisite_rct_3arm",
      "ground_truth": {
        "sample_size": 30,
        "power": 0.676,
        "f2": 0.25
      },
      "tolerance": {
        "sample_size": 1,
        "power": 0.0135,
        "f2": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mrt3arm",
        "origin": "WebPower::wp.mrt3arm CRAN documentation",
        "variation": "mrt3_n30_J30_pwr"
      },
      "reference_code": "library(WebPower)\nwp.mrt3arm(n=30, f1=0.25, f2=0.25, J=30, tau=0.10, sg2=1.0, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-anova-143",
      "template": "one_way_anova",
      "difficulty": "advanced",
      "question": "A sports medicine physician wants to compare sleep quality scores across 8 treatment groups. Expecting a small effect size (Cohen's f = 0.1), at significance level of 0.01 with 80% power, how many participants per group are needed?",
      "expected_template": "one_way_anova",
      "ground_truth": {
        "sample_size": 1988,
        "power": 0.8,
        "effect_size_f": 0.1
      },
      "tolerance": {
        "sample_size": 40,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.anova",
        "origin": "WebPower::wp.anova CRAN documentation",
        "variation": "anova_f010_k8_a01"
      },
      "reference_code": "library(WebPower)\nwp.anova(f=0.10, k=8, power=0.80, alpha=0.01)",
      "tier": 3
    },
    {
      "id": "t3-wp-kanova-144",
      "template": "factorial_anova",
      "difficulty": "advanced",
      "question": "A allergist is designing a 2 x 2 factorial design to study reaction time (ms). The expected cell means are specified with SD = 1. At significance level of 0.05 with 80% power, how many participants per cell are needed?",
      "expected_template": "factorial_anova",
      "ground_truth": {
        "sample_size": 536,
        "power": 0.8,
        "effect_size_f": 0.15
      },
      "tolerance": {
        "sample_size": 11,
        "power": 0.016,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.kanova",
        "origin": "WebPower::wp.kanova CRAN documentation",
        "variation": "kanova_f015_ndf4_ng10"
      },
      "reference_code": "library(WebPower)\nwp.kanova(f=0.15, ndf=4, ng=10, power=0.80, alpha=0.05)",
      "tier": 3
    },
    {
      "id": "t3-wp-rmanova-145",
      "template": "repeated_measures_anova",
      "difficulty": "advanced",
      "question": "A urologist plans a repeated-measures study with 3 time points measuring lung function measures. Expecting a small effect size (Cohen's f = 0.15), at significance level of 0.05 with 90% power, how many subjects are needed?",
      "expected_template": "repeated_measures_anova",
      "ground_truth": {
        "sample_size": 1269,
        "power": 0.9,
        "effect_size_f": 0.15
      },
      "tolerance": {
        "sample_size": 26,
        "power": 0.018,
        "effect_size_f": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.rmanova",
        "origin": "WebPower::wp.rmanova CRAN documentation",
        "variation": "rmanova_4g6m_complex"
      },
      "reference_code": "library(WebPower)\nwp.rmanova(f=0.15, ng=4, nm=6, nscor=0.75, power=0.90, alpha=0.05, type=2)",
      "tier": 3
    },
    {
      "id": "t3-wp-regression-146",
      "template": "linear_regression",
      "difficulty": "advanced",
      "question": "A hematologist is building a linear regression model to predict blood glucose levels. The expected model R\u00b2 is 0.02. The anticipated an effect size of f\u00b2 = 0.02. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "linear_regression",
      "ground_truth": {
        "sample_size": 822,
        "power": 0.8,
        "f2": 0.02
      },
      "tolerance": {
        "sample_size": 17,
        "power": 0.016,
        "f2": 0.005
      },
      "source": {
        "package": "WebPower",
        "function": "wp.regression",
        "origin": "WebPower::wp.regression CRAN documentation",
        "variation": "reg_incr_small_p15p5"
      },
      "reference_code": "library(WebPower)\nwp.regression(f2=0.02, p1=15, p2=5, power=0.80, alpha=0.05, type=2)",
      "tier": 3
    },
    {
      "id": "t3-wp-logistic-147",
      "template": "logistic_regression",
      "difficulty": "advanced",
      "question": "A clinical nutritionist is planning a logistic regression study for generalized anxiety disorder with baseline probability 0.05 and expected probability 0.1 under the alternative. At significance level of 0.05 with 80% power, how many subjects are needed?",
      "expected_template": "logistic_regression",
      "ground_truth": {
        "sample_size": 905,
        "power": 0.8
      },
      "tolerance": {
        "sample_size": 19,
        "power": 0.016
      },
      "source": {
        "package": "WebPower",
        "function": "wp.logistic",
        "origin": "WebPower::wp.logistic CRAN documentation",
        "variation": "logreg_rare_p05v10"
      },
      "reference_code": "library(WebPower)\nwp.logistic(p0=0.05, p1=0.10, power=0.80, alpha=0.05, family=\"Bernoulli\")",
      "tier": 3
    },
    {
      "id": "t3-wp-mediation-148",
      "template": "mediation",
      "difficulty": "advanced",
      "question": "A rehabilitation specialist is designing a mediation analysis to examine whether the effect of a treatment on an outcome is mediated by an intermediate variable. The path coefficients are a = 0.1 and b = 0.15. At significance level of 0.05 with 80% power, how many subjects are needed to detect the indirect effect?",
      "expected_template": "mediation",
      "ground_truth": {
        "sample_size": 1130,
        "power": 0.8
      },
      "tolerance": {
        "sample_size": 23,
        "power": 0.016
      },
      "source": {
        "package": "WebPower",
        "function": "wp.mediation",
        "origin": "WebPower::wp.mediation CRAN documentation",
        "variation": "med_small_a010_b015"
      },
      "reference_code": "library(WebPower)\nwp.mediation(a=0.10, b=0.15, varx=1, varm=1, vary=1, power=0.80, alpha=0.05)",
      "tier": 3
    }
  ]
}